500-mg dried ginger-powder capsules × Reduction of office systolic blood pressure in adults with metabolic syndrome

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Met	Full text not readStored summary read	N01 · Evidence conditionWhich independent question does this table check?Required	The original claim concerns office systolic blood-pressure reduction in adults with metabolic syndrome. Both sets of population/intervention details connect metabolic syndrome, exclusion of antihypertensive users, mean baseline SBP about 121, dried-powder 500 mg capsules at 2 g/day for 12 weeks, starch placebo plus the same lifestyle counseling, and between-group office SBP change. S01 S02	This verifies the link between the original record and the selected narrow question. It does not establish a reduction, full-text reading or new efficacy certification.	The comparison of between-group office SBP change in adults with metabolic syndrome not using antihypertensives: dried-powder 500 mg capsules at 2 g/day for 12 weeks versus starch placebo plus the same lifestyle counseling	Material needed: If the boundary changes, an original report specifying the population, endpoint, formulation, comparison and timing. This records needed materials; no new research was executed.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionHave direct and meta-analysis reports been kept from being double-counted as independent replications?Required	The current research and citation summaries each contain 2 entries. The Rahimlou 2019 direct report and Karimi 2026 meta-analysis are distinguished. The meta-analysis reports 12 unique RCTs and 13 SBP effect sizes; inclusion of S01 and the list of original trial families are unavailable. S01 S02	The bibliographic identities of both reports are retained, but the mapping and overlap of 12 original trials and 13 effects were not compared. The number of unique independent trials and total participants remain unconfirmed.	The identities of the Rahimlou 2019 direct report and Karimi 2026 synthesis, the included-trial table, and whether the direct trial was included	Material needed: The meta-analysis included-trial/effect mapping table, registration, and a list of related direct-trial reports. This records needed materials; no new research was executed.
3	Met	Full text not readStored summary read	N03 · Evidence conditionWhat is the scope of the diabetes-only −1.62 mmHg reference without a bibliography?Required	The Korean/English counterview and counterpoint mention −1.62 mmHg from a diabetes-only 2026 analysis. The current 2 research/citation entries identify the direct trial and broader meta-analysis; a separate bibliography, denominator, CI and P value for this diabetes analysis are not linked. S01 S02	The limited identity and attribution boundary of the retained wording was verified. It is neither deleted nor invented as S03 or a new trial family; this does not mean the study is absent from all literature.	Check the value in the Korean/English counterview and counterpoint, and whether a separate bibliography, design, population, denominator and CI are linked	Material needed: The actual bibliography, included-trial table and original result location for the diabetes-only analysis. This records needed materials; no new research was executed.
4	Met	Full text not readStored summary read	N04 · Evidence conditionWhich materials were actually read, and which remain unread?Required	Both report summaries, Korean/English evidence and bibliographies, and all original values in the retained record were actually read. Each PubMed URL and bibliographic DOI/PMCID is a retained entry point. External abstracts, full texts, PMC material, registration and supplements were not accessed, acquired or read in this work. S01 S02	Actual acquisition and reading apply only to locally retained summaries. Current external existence and successful responses remain unverified; they are not labeled as access failures or acquired full texts.	The existence, access, acquisition, reading levels and links for the current retained summary and external index, DOI, PMC, registration and supplements	Material needed: Actual responses, acquired original bytes, versions, reading dates and exact links for each material. This records needed materials; no new research was executed.
5	Partly verified	Full text not readStored summary read	N05 · Evidence conditionWhich adults with metabolic syndrome were studied, and how far does applicability extend?Required	The population details in both languages specify adults with metabolic syndrome, mean baseline SBP about 121 mmHg, and exclusion of antihypertensive users. Differences in meta-analysis populations and baseline blood pressure appear in the rationale, but details of diagnosis, age, recruitment and baseline distributions by group in the direct trial remain unverified. S01 S02	The stated population characteristics were verified, but applicability to people treated for hypertension, representativeness and detailed eligibility criteria were not newly verified.	Diagnosis, eligibility and exclusion criteria, age, setting, baseline SBP, medication use and characteristics by group	Material needed: The direct trial's eligibility/exclusion criteria and baseline table by group, and meta-analysis results by population. This records needed materials; no new research was executed.
6	Partly verified	Full text not readStored summary read	N06 · Evidence conditionWhich ginger formulation, route and dose were administered?Required	The original material, formulation, route and dose are Zingiber officinale Roscoe rhizome; dried ginger-powder 500 mg capsules; unclear assay-table units; oral administration; and 2 g/day. Standardized extracts, essential oil and food are distinguished in the product information. S01	The nominal powder formulation and dose are retained, but assay units, standardization, batch information and actual adherence-adjusted intake are unverified. Capsule counts and active-constituent amounts were not calculated.	Dried rhizome-powder 500 mg capsules, oral 2 g/day, assay-table units and batch information, and actual consumption	Material needed: Product specifications, assay-table units, batch documentation and actual administration records. This records needed materials; no new research was executed.
7	Partly verified	Full text not readStored summary read	N07 · Evidence conditionWhat did the placebo and lifestyle counseling actually compare?Required	The recorded comparator is starch placebo plus the same lifestyle counseling, as also stated in English. The actual content of counseling, sensory matching of the placebo, and treatment or lifestyle changes by group could not be verified in the current retained summary. S01	The placebo/counseling comparison is verified, but this does not establish that all actual behavior and medication changes were identical.	The starch placebo, the content of identical lifestyle counseling, sensory matching, and actual treatment changes by group	Material needed: Placebo composition, counseling procedures, and records of concomitant interventions and changes by group. This records needed materials; no new research was executed.
8	Partly verified	Full text not readStored summary read	N08 · Evidence conditionWhich outcome, unit, change and time point does 12-week SBP represent?Required	The selected endpoint is between-group change in office SBP at 12 weeks, and the duration is 12 weeks of treatment. The scope note limits the question to office SBP; the reader answer states that matching SBP prespecification as the 1st endpoint is unclear. S01	Attribution to 12-week office SBP change is verified, but the actual prespecified hierarchy, measurement method and assessment schedule are unverified. DBP, ambulatory pressure and endothelial function do not replace it.	Between-group change from baseline in 12-week office systolic blood pressure, mmHg, prespecified hierarchy and measurement conditions	Material needed: The 12-week result table, assessment method, and SBP hierarchy in the protocol/statistical analysis plan. This records needed materials; no new research was executed.
9	Partly verified	Full text not readStored summary read	N09 · Evidence conditionAre the adjusted P value and raw change difference from rounded means the same estimate?Required	The direct result is retained as adjusted between-group P=.165; raw change difference from rounded means −1.12 mmHg; adjusted CI unverified. The reader answer's adjusted P=.165 and the raw rounded change difference of −1.12 mmHg are each preserved. S01	The distinction between the P value and raw difference is retained, but the adjusted effect/CI, exact raw table/model and analysis denominators by group are unverified. They were neither substituted as adjusted values nor recalculated.	The separate analyses, directions and CIs for adjusted between-group P=.165 and the raw −1.12 mmHg from rounded means	Material needed: The exact raw result table, adjusted estimate/model/covariates, CI and denominators by group. This records needed materials; no new research was executed.
10	Partly verified	Full text not readStored summary read	N10 · Evidence conditionWhich denominators are represented by 38 randomized participants and 37 completers (19/18)?Required	The retained direct-trial denominator is 38 randomized participants and 37 completers (19/18). The 38 are described as randomized and the 37 as completers; the ginger/placebo arm mapping of 19/18 is not explicitly stated in the original record. S01	Do not infer that 19 means ginger and 18 means placebo. Data on randomized/analyzed/completing denominators by group, ITT/PP, reasons for dropout and their handling are unavailable, so efficacy and safety denominators cannot be confirmed.	The total 38 randomized, 37 completers, arm mapping of 19/18, denominators randomized/analyzed/completing by group, and handling of missingness	Material needed: Participant flow by group, completion/analysis tables, missing-data handling and the statistical analysis plan. This records needed materials; no new research was executed.
11	Met	Full text not readStored summary read	N11 · Evidence conditionAre the nonsignificant direct result and positive supportive meta-analysis signal both retained?Required	The original values are retained separately: direct adjusted between-group P=.165; raw change difference from rounded means −1.12 mmHg; adjusted CI unverified; and meta-analysis WMD −5.03 mmHg, 95% CI −8.49~−1.57, P=.004, with low certainty. The reader answer states that the direct result was not established and E0 was not assigned because prespecification is unclear; the key explanation and rationale limit the pooled signal by low certainty and heterogeneity. The diabetes −1.62 reference is background without a linked identity. S01 S02	The favorable meta-analysis value did not erase the nonsignificant direct result. Numerical differences across populations or analyses were not converted into conflicting data under the same comparison, effect 0 or equivalence.	Direct P=.165 and raw −1.12, and meta-analysis WMD −5.03/95% CI −8.49~−1.57/P=.004, low certainty and the diabetes background value −1.62	Material needed: Exact result tables by report, included trials and heterogeneity in the meta-analysis, and the identity of the diabetes analysis. This records needed materials; no new research was executed.
12	Met	Full text not readStored summary read	N12 · Evidence conditionWhich dates and preservation, search and correction scope support these statements?Required	The original verdict date is 2026-09-08, and the correction record describes the 2026-09-14 English placeholder correction, C→C. The actual source, Korean/English content, generic English evidence wording, axes, empty subclaims, deliberation and URLs were retained. This work converts the retained summary; new external full-text, abstract, registration, correction and retraction queries total 0. S01 S02	The review date concerns the current reading event; the original verdict date concerns historical record review. The historical search cutoff, individual access dates and complete current literature status were not retrospectively verified.	The original verdict date 2026-09-08, correction date 2026-09-14, actual current review date, retained record and unread external scope	Material needed: Historical search/access records and original publication, correction and retraction records. This records needed materials; no new research was executed.
13	Partly verified	Full text not readStored summary read	N13 · Evidence conditionWhat do university support and the manufacturer's product name establish about funding and independence?Supplementary; required for independence claims	The direct-trial funding field states university support, with the manufacturer's product name separate from funding. The rationale's description of university support as a strength and the I2 axis are retained as history. Product provision, author employment/patents, detailed COI and institutional relationships are not established in this retained summary. S01	Only the statements of university support and the distinction between the manufacturer's product name and funding were verified. Company funding, independent teams or absence of all COI are not confirmed.	The direct trial's funding, product provision, authors/institutions, employment, patents and COI details	Material needed: Original funding, acknowledgment and COI locations, product-support documentation and author relationships for the direct trial. This records needed materials; no new research was executed.
14	Partly verified	Full text not readStored summary read	N14 · Evidence conditionWhat level of verification is represented by the meta-analysis authors' declaration of no conflicts?Supplementary; required for independence claims	The retained meta-analysis funding field states that the authors declared no conflicts of interest. The current record provides only the meta-analysis declaration; it does not provide funding, product/author relationships or institutional families for each included trial. S02	The meta-analysis authors' declaration is not used to verify independence, absence of bias or absence of product support across all 12 original trials.	Declared COI, funding and institutions of the meta-analysis, and funding/author relationships in the original trials	Material needed: Original meta-analysis COI/funding locations and a table of funding and institutions by included trial. This records needed materials; no new research was executed.
15	Partly verified	Full text not readStored summary read	N15 · Evidence conditionHow were randomization, concealment and blinding actually performed in the direct trial?Required	The direct design is described as randomized, double-blind and placebo-controlled in both languages. Sequence generation, concealment, who was blinded, blinding success and baseline balance by group remain unverified. S01	The retained design label was verified. It does not certify that randomization, confounding or measurement issues were resolved, and unverified design details are not labeled not applicable.	The randomized, double-blind placebo-controlled design label, sequence generation, concealment and baseline balance	Material needed: Original methods, baseline tables by group, and randomization, concealment and blinding procedures. This records needed materials; no new research was executed.
16	Unverified	Full text not readStored summary read	N16 · Evidence conditionCould adherence, concomitant treatment or changes in counseling be mixed with the effect?Required	The population/intervention details specify the same lifestyle counseling, starch placebo and exclusion of antihypertensive users. The retained summary lacks actual adherence, discontinuation, counseling implementation, concomitant medications/rescue treatment, changes by group and their handling. S01	Original material needed to verify the influence of actual deviations and treatment changes beyond the comparison specification on SBP analysis was not read. Absence of changes is not assumed.	Actual consumption, discontinuation, lifestyle counseling, medications/rescue treatment, deviations and their handling by group	Material needed: Consumption/counseling, concomitant medication, rescue-treatment, deviation and analysis-handling records. This records needed materials; no new research was executed.
17	Unverified	Full text not readStored summary read	N17 · Evidence conditionUnder which conditions and procedures was office SBP measured?Required	The retained endpoint and population/intervention details specify 12-week office SBP, but do not provide devices, rest, repeated measurements/averaging, assessors or measurement timing by group. The double-blind label is not a specific assessor procedure. S01	Material establishing actual measurement conditions and differences by group for the selected office SBP remains unread. An objective endpoint does not remove measurement limitations.	Devices, rest, repeated measurements/averaging, assessors, blinding and assessment timing by group	Material needed: Original measurement procedures and assessment schedules, including error and missing-measurement records. This records needed materials; no new research was executed.
18	Partly verified	Full text not readStored summary read	N18 · Evidence conditionWhich population and intervention effect does the adjusted analysis estimate?Required	The reader answer and rationale describe a 37-completer trial, small-sample/completer-analysis limitations and adjusted P=.165. The original denominator is 38 randomized and 37 completing; the result's −1.12 is a raw change difference from rounded means. S01	The completer-analysis and adjusted-P descriptions are verified, but exact analysis denominators/populations, ITT/PP, estimands, covariates/models and missing-data handling are unverified. They are not filled in as ANCOVA or ITT.	Completer analysis, ITT/PP, adjustment covariates/model, estimand and analysis denominator	Material needed: Exact analysis tables, statistical analysis plan, model, analysis population and missing-data handling. This records needed materials; no new research was executed.
19	Unverified	Full text not readStored summary read	N19 · Evidence conditionCan the adjusted interval and clinical importance of the direct effect be assessed?Required	The direct result and rationale explicitly leave the adjusted CI and clinical threshold unverified. The meta-analysis's 95% CI −8.49~−1.57 belongs to a separate pooled WMD and is not the direct trial's adjusted interval. S01 S02	The relationship between the direct effect's adjusted interval and a justified important SBP difference was not verified. P values, sample size and the meta-analysis CI do not establish sufficiency.	The direct trial's adjusted effect/95% CI, variance/denominators by group and a justified important SBP difference	Material needed: The direct adjusted CI, estimate/variance and basis for clinical importance. This records needed materials; no new research was executed.
20	Unverified	Full text not readStored summary read	N20 · Evidence conditionWere prespecified SBP endpoints, analyses and registration compared with actual reporting?Required	The direct-trial registration field is unverified, and the evidence weight describes the principal direct trial with unverified prespecification. The Korean/English reader answers state that matching SBP prespecification is unclear. Registration, the protocol/statistical analysis plan and change history were not read in this work. S01	The selected endpoint label is distinguished from actual confirmation of the prespecified 1st endpoint/statistical analysis plan. Unverified registration does not establish nonregistration or selective reporting, and the original EX is not changed to E0.	Original trial registration, protocol/statistical analysis plan, the hierarchy of 12-week SBP and analysis/multiplicity plans	Material needed: Actual original-trial registration, protocol/statistical analysis plan, change history and the corresponding result tables. This records needed materials; no new research was executed.
21	Partly verified	Full text not readStored summary read	N21 · Evidence conditionHow different are the supportive meta-analysis's unique trials, effects and conditions?Required	The meta-analysis reports 12 unique RCTs and 13 SBP effect sizes; WMD −5.03 mmHg, 95% CI −8.49~−1.57, P=.004, with low certainty. The rationale specifies differences in baseline pressure, disease, formulation and dose, and some 2nd blood-pressure endpoints. Included trials, mapping of the 13 effects, inclusion of S01, and detailed heterogeneity/GRADE tables remain unread. S01 S02	The reported pooled result, low certainty and different conditions are retained. The 13 effects are not counted as 13 unique studies, nor as 1+12 independent trials, and GRADE was not newly performed.	The mapping of 12 unique RCTs and 13 SBP effects, populations/baseline pressure/formulations/doses/endpoint hierarchy, heterogeneity and detailed GRADE domains	Material needed: Meta-analysis included-trial/effect mapping tables, subgroup/heterogeneity analyses and GRADE domain tables. This records needed materials; no new research was executed.
22	Unverified	Full text not readStored summary read	N22 · Evidence conditionDoes the material answer questions about optimal dose, long-term persistence or subgroups?Supplementary; required for extension claims	The current direct comparison specifies 2 g/day for 12 weeks. The advertising interpretation rejects an optimal-dose conclusion for 2 g or more, and dose-response in the meta-analysis title does not provide a direct dose comparison. Long-term/post-withdrawal follow-up, prespecified subgroups and the diabetes analysis identity are also unverified. S01 S02	Extension material beyond the narrow question was not read. Not every extension trial is made mandatory, and direct dose, persistence or subgroup effects are not promoted to verified status.	Direct dose comparisons, withdrawal/long-term follow-up, prespecified subgroups/interactions and the identity of the diabetes analysis	Material needed: Direct dose-comparison trials, post-withdrawal/long-term follow-up, subgroup plans and original results. This records needed materials; no new research was executed.
23	Partly verified	Full text not readStored summary read	N23 · Evidence conditionDoes an SBP change also answer questions about event prevention or medication replacement?Supplementary; required for clinical extension claims	The scope note limits the verdict to office SBP, and the advertising interpretation places antihypertensive replacement and cardiovascular-event prevention outside the evidence. The key explanation's roughly 5 mmHg signal is a low-certainty short-term pooled estimate, not a result limited to hypertension-treatment trials. S01 S02	The boundary between the selected endpoint and clinical extensions is verified, but direct event/treatment-replacement results, denominators and follow-up are unverified within the current material. This gap does not remove the SBP report.	Separate questions and direct evidence for the selected SBP outcome versus cardiovascular events, quality of life, mortality and antihypertensive replacement	Material needed: Separate plans, denominators, follow-up and results actually comparing events or treatment replacement. This records needed materials; no new research was executed.
24	Partly verified	Full text not readStored summary read	N24 · Evidence conditionWhat level of harm verification is represented by the caution in the efficacy summary?Supplementary; required for safety claims	The original safety label is Caution. The retained safety wording is: monitor dizziness, hypotension and possible interactions when combined with blood-pressure medicines, and do not reduce prescribed treatment on one's own. Actual observed adverse events, collection methods, event/safety denominators and discontinuation results are not linked in the current summaries of both efficacy reports. S01 S02	The general caution is retained, but it does not verify actual harm records for the same exposure and population. An efficacy summary is not filled in as evidence of safety.	Actual adverse events, collection methods, denominators, discontinuations and the original caution for the same population, powder and period	Material needed: Adverse-event collection methods, event/exposure denominators, discontinuations and observation periods for the trial. This records needed materials; no new research was executed.
25	Unverified	Full text not readStored summary read	N25 · Evidence conditionAre dizziness and hypotension actual observed events or cautionary statements?Supplementary; required for harm questions	Dizziness, hypotension and interactions are listed in the current safety caution and product information. Observed values for event diagnosis, occurrence/worsening, collection, severity and discontinuation could not be verified in the retained summary. S01 S02	Recommendations are not converted into actual events or confirmed diagnoses, and absence of adverse-event reporting in the unread external article is not established.	Trial event definitions/adjudication, systematic or spontaneous collection, severity and discontinuation records	Material needed: Original adverse-event definitions, collection/adjudication procedures, and event, severity and discontinuation tables. This records needed materials; no new research was executed.
26	Unverified	Full text not readStored summary read	N26 · Evidence conditionIs the temporal relationship between exposure and actual harm verified?Supplementary; required for harm questions	Nominal administration of 2 g/day for 12 weeks is recorded. Actual harm onset, discontinuation, recovery, re-exposure and event-specific observation periods for this trial are not provided. S01	Treatment duration is not converted into event-onset or recovery timing. Original records needed to verify temporal order and harm causality remain unread.	Starting 2 g/day, the 12-week period, event onset/recovery, discontinuation/re-exposure and observation periods	Material needed: Exposure/event timelines and records of discontinuation, recovery and re-exposure. This records needed materials; no new research was executed.
27	Unverified	Full text not readStored summary read	N27 · Evidence conditionAgainst which comparator were harms actually compared?Supplementary; required for comparative harm claims	Starch placebo plus the same lifestyle counseling specifies the efficacy comparison. Actual adverse events by group and comparative harm estimates are unavailable in the retained summary. S01	Verifying an efficacy comparator does not verify comparative harm results. Background incidence or increased risk is not extrapolated.	Actual adverse events and comparative estimates involving placebo, background conditions and concomitant medications	Material needed: Adverse-event tables by group and event-specific comparison denominators/analyses. This records needed materials; no new research was executed.
28	Unverified	Full text not readStored summary read	N28 · Evidence conditionAre denominators and exposure time available for harm frequency?Supplementary; required for incidence claims	The 38 randomized participants, 37 completers (19/18), and the meta-analysis's 12 RCTs/13 effects are efficacy/reporting denominators. No linked adverse-event table supplies a safety-analysis denominator, people/event counts, exposed participants or exposure time. S01 S02	The denominators, time and events needed to calculate current harm incidence are unverified. Do not create 0 events/0% or reuse efficacy denominators as safety denominators.	Numbers exposed or in the safety analysis, people with events versus event counts, and exposure/follow-up time	Material needed: Safety-analysis populations, people/event counts and exposure-duration tables. This records needed materials; no new research was executed.
29	Unverified	Full text not readStored summary read	N29 · Evidence conditionWhat alternative explanations involve concomitant medications, baseline conditions or lifestyle changes?Supplementary; required for causal harm claims	The direct trial's population details exclude antihypertensive users, whereas the safety wording cautions about combining ginger with blood-pressure medicines. Records of other concomitant medications, underlying diseases, lifestyle changes, actual alternative explanations for harm or their adjustment are unavailable for this trial. S01	A general combination-use caution is not attributed as an observed interaction in a direct trial excluding antihypertensive users. Absence of other causes is not inferred.	Exclusion of antihypertensive users, other medications/diseases, lifestyle counseling, dose and their relationship to actual harms	Material needed: Concomitant medications, underlying conditions, lifestyle changes and adjustment records in harm cases/trials. This records needed materials; no new research was executed.
30	Unverified	Full text not readStored summary read	N30 · Evidence conditionWhat is known about harm collection, reporting and loss to follow-up?Supplementary; required for harm questions	Direct-trial completion counts and completer-analysis limitations are retained, but original records of adverse-event collection, selection/recall/detection, missing safety follow-up and discontinuation reasons were not read in this work. S01	Unverified information in a summary is not converted into confirmed nonreporting of harms in the original article, absence of harm or a known extent of missingness.	Collection of all adverse events, selection/recall/detection, missing safety follow-up and reasons for discontinuation/dropout	Material needed: Original collection procedures and the reporting scope for all adverse events, discontinuations and dropouts. This records needed materials; no new research was executed.
31	Unverified	Full text not readStored summary read	N31 · Evidence conditionAre the same harm events linked in other independent material?Supplementary; required for repeated harm claims	The current retained material contains a direct efficacy report, a meta-analysis and general safety cautions. Identities and repeat reporting/citation of separate independent harm events or materials are not linked, and no new safety search was performed. S01 S02	Meta-analysis, Korean/English repetition and caution wording are not counted as independent events. Unconfirmed unique harm replication or total safety-study counts do not mean 0 studies.	Identities of unique events/study families, reports and repeat citations, matched exposure/events and regulatory material	Material needed: Independent original safety reports with specified identities and exposures/events, and a repeat-citation mapping table. This records needed materials; no new research was executed.
32	Unverified	Full text not readStored summary read	N32 · Evidence conditionDoes the material address long-term or rare harms and other vulnerable populations?Supplementary; required for overall safety claims	The current direct comparison concerns adults with metabolic syndrome not using antihypertensives over 12 weeks. Direct safety material on long-term or rare events, combined medication use, pregnancy and other vulnerable populations is outside the current verified scope. S01 S02	A limited efficacy population/period is not extended into overall safety. The narrow SBP question does not require every long-term or rare-harm trial.	Exposure beyond 12 weeks and separate direct material on rare events, medication users, pregnancy/baseline risk and interactions	Material needed: Safety observation, comparison and registration material suited to the target vulnerable population and duration. This records needed materials; no new research was executed.
33	Met	Full text not readStored summary read	N33 · Evidence conditionDoes the current caution wording describe a signal, incidence or causality?Supplementary; required for causal harm or safety claims	The current caution and wording about monitoring combined use with blood-pressure medicines and avoiding self-directed dose reduction are retained. They do not verify event counts, comparative risk, causality or a safety grade in this trial; harm design, denominators, timing and alternatives remain unverified. S01 S02	This verifies the interpretation boundary and retained uncertainty of a cautionary statement. It does not create a new judgment that harm occurred or safety was established, or provide personal dosing instructions.	The reporting level of the original caution, actual design/events/denominators/timing/alternatives and possible interpretation	Material needed: Actual original harm material linking design, comparison, denominators, timing and alternative explanations. This records needed materials; no new research was executed.

No items match your search or filter.

33 itemsWhat the statuses mean

Assessment scope

Stored-material review date: 2026-10-06
Original evidence cut-off: 2026-09-08
Scope actually checked: Retained Korean/English summaries and case-specific condition/application records. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: The material date 2026-10-06 concerns retained-summary review. Observations were applied after the conditions were frozen; historical records of later observation-wording and external-unread display changes were retained. The original verdict date 2026-09-08 and correction date 2026-09-14 are not new-search or external-full-text-reading dates.
Population: Adults with metabolic syndrome; mean baseline SBP about 121 mmHg; antihypertensive users excluded
Ingredient, formulation and route: 500-mg dried ginger-powder capsules; assay units unclear
Dose: 2 g/day
Comparator: Starch placebo plus the same lifestyle counseling
Measured outcome: Between-group difference in 12-week office SBP change
Duration: 12 weeks
Questions outside this scope: Other ginger formulations or hypertension-treatment effects in antihypertensive users; DBP, ambulatory blood pressure and endothelial function; Optimal dose, long-term persistence and direct subgroup effects; Cardiovascular-event prevention and antihypertensive replacement; Turning the diabetes −1.62 background reference without bibliography into a newly verified report; Establishing overall safety, causal harms or incidence

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Rahimlou M et al. Diabetol Metab Syndr. 2019. PMID: 31275882. PMCID: PMC6582048. DOI: 10.1007/s40200-019-00397-z.

PubMed

Material type: Stored summary of a direct dried-ginger-powder trial in metabolic syndrome
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Findings recorded in the stored summary: Adjusted between-group P=.165; raw change difference from rounded means −1.12 mmHg; adjusted CI unverified
Record level: These are retained reported values and limitations, not current full-text verification or recalculation.
Study overlap and independent replication: The direct report and meta-analysis are not added as independent replications of the same question. The 12 unique RCTs and 13 SBP effects are wording from the retained meta-analysis; inclusion of the direct trial, overlap with other meta-analyses, unique trials and total participants remain unverified. The diabetes background reference is not added as a separate report.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Locally retained; stored summary read	Acquired	Stored existing review summary read	The linked summary, Korean/English evidence and bibliography were read in the retained record. This does not verify original article bytes or full text. The roles of 38 randomized participants and 37 completers (19/18) are preserved. Arm mapping, adjusted effect/CI, actual SBP prespecification, registration and observed harm records remain unverified. The material date 2026-10-06 concerns retained-summary review. Observations were applied after the conditions were frozen; historical records of later observation-wording and external-unread display changes were retained. The original verdict date 2026-09-08 and correction date 2026-09-14 are not new-search or external-full-text-reading dates.
External bibliography and abstract	Existence, availability and acquisition unverified; not read	Access not attempted	Not read	This is a retained PubMed entry point. Current response and abstract reading were not verified. The roles of 38 randomized participants and 37 completers (19/18) are preserved. Arm mapping, adjusted effect/CI, actual SBP prespecification, registration and observed harm records remain unverified. The material date 2026-10-06 concerns retained-summary review. Observations were applied after the conditions were frozen; historical records of later observation-wording and external-unread display changes were retained. The original verdict date 2026-09-08 and correction date 2026-09-14 are not new-search or external-full-text-reading dates.
Original full text and DOI entry point	Existence, availability and acquisition unverified; not read	Access not attempted	Not read	This full-text entry point was constructed from the DOI in the retained bibliography. Full-text existence, access, downloading and reading are unverified. The roles of 38 randomized participants and 37 completers (19/18) are preserved. Arm mapping, adjusted effect/CI, actual SBP prespecification, registration and observed harm records remain unverified. The material date 2026-10-06 concerns retained-summary review. Observations were applied after the conditions were frozen; historical records of later observation-wording and external-unread display changes were retained. The original verdict date 2026-09-08 and correction date 2026-09-14 are not new-search or external-full-text-reading dates.
PMC full-text entry point	Existence, availability and acquisition unverified; not read	Access not attempted	Not read	This full-text entry point was constructed from the retained PMCID. Current response, full text and accessibility are unverified; it is another entry point for the same report, not a separate trial. The roles of 38 randomized participants and 37 completers (19/18) are preserved. Arm mapping, adjusted effect/CI, actual SBP prespecification, registration and observed harm records remain unverified. The material date 2026-10-06 concerns retained-summary review. Observations were applied after the conditions were frozen; historical records of later observation-wording and external-unread display changes were retained. The original verdict date 2026-09-08 and correction date 2026-09-14 are not new-search or external-full-text-reading dates.
Trial registration	Existence, availability and acquisition unverified; not read	Access not attempted	Not read	Unverified registration does not establish that registration was absent. Meta-analysis registration and included-trial registration are distinguished; no registration ID or location was created. The roles of 38 randomized participants and 37 completers (19/18) are preserved. Arm mapping, adjusted effect/CI, actual SBP prespecification, registration and observed harm records remain unverified. The material date 2026-10-06 concerns retained-summary review. Observations were applied after the conditions were frozen; historical records of later observation-wording and external-unread display changes were retained. The original verdict date 2026-09-08 and correction date 2026-09-14 are not new-search or external-full-text-reading dates.
Original supplementary material	Existence, availability and acquisition unverified; not read	Access not attempted	Not read	Supplement existence, exact location and original bytes are unverified. This does not establish supplement absence or actual access failure. The roles of 38 randomized participants and 37 completers (19/18) are preserved. Arm mapping, adjusted effect/CI, actual SBP prespecification, registration and observed harm records remain unverified. The material date 2026-10-06 concerns retained-summary review. Observations were applied after the conditions were frozen; historical records of later observation-wording and external-unread display changes were retained. The original verdict date 2026-09-08 and correction date 2026-09-14 are not new-search or external-full-text-reading dates.

S02 · Karimi M et al. J Hum Nutr Diet. 2026;39:e70329. PMID: 42566667. PMCID: PMC13450692. DOI: 10.1111/jhn.70329.

PubMed

Material type: Stored summary of a GRADE dose-response meta-analysis
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Findings recorded in the stored summary: WMD −5.03 mmHg, 95% CI −8.49~−1.57, P=.004; low certainty of evidence
Record level: These are retained reported values and limitations, not current full-text verification or recalculation.
Study overlap and independent replication: The direct report and meta-analysis are not added as independent replications of the same question. The 12 unique RCTs and 13 SBP effects are wording from the retained meta-analysis; inclusion of the direct trial, overlap with other meta-analyses, unique trials and total participants remain unverified. The diabetes background reference is not added as a separate report.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Locally retained; stored summary read	Acquired	Stored existing review summary read	The linked summary, Korean/English evidence and bibliography were read in the retained record. This does not verify original article bytes or full text. The 12 unique RCTs and 13 SBP effects are wording from the retained report. Included trials, overlap, analysis-specific denominators, heterogeneity and detailed GRADE domains remain unverified. The material date 2026-10-06 concerns retained-summary review. Observations were applied after the conditions were frozen; historical records of later observation-wording and external-unread display changes were retained. The original verdict date 2026-09-08 and correction date 2026-09-14 are not new-search or external-full-text-reading dates.
External bibliography and abstract	Existence, availability and acquisition unverified; not read	Access not attempted	Not read	This is a retained PubMed entry point. Current response and abstract reading were not verified. The 12 unique RCTs and 13 SBP effects are wording from the retained report. Included trials, overlap, analysis-specific denominators, heterogeneity and detailed GRADE domains remain unverified. The material date 2026-10-06 concerns retained-summary review. Observations were applied after the conditions were frozen; historical records of later observation-wording and external-unread display changes were retained. The original verdict date 2026-09-08 and correction date 2026-09-14 are not new-search or external-full-text-reading dates.
Original full text and DOI entry point	Existence, availability and acquisition unverified; not read	Access not attempted	Not read	This full-text entry point was constructed from the DOI in the retained bibliography. Full-text existence, access, downloading and reading are unverified. The 12 unique RCTs and 13 SBP effects are wording from the retained report. Included trials, overlap, analysis-specific denominators, heterogeneity and detailed GRADE domains remain unverified. The material date 2026-10-06 concerns retained-summary review. Observations were applied after the conditions were frozen; historical records of later observation-wording and external-unread display changes were retained. The original verdict date 2026-09-08 and correction date 2026-09-14 are not new-search or external-full-text-reading dates.
PMC full-text entry point	Existence, availability and acquisition unverified; not read	Access not attempted	Not read	This full-text entry point was constructed from the retained PMCID. Current response, full text and accessibility are unverified; it is another entry point for the same report, not a separate trial. The 12 unique RCTs and 13 SBP effects are wording from the retained report. Included trials, overlap, analysis-specific denominators, heterogeneity and detailed GRADE domains remain unverified. The material date 2026-10-06 concerns retained-summary review. Observations were applied after the conditions were frozen; historical records of later observation-wording and external-unread display changes were retained. The original verdict date 2026-09-08 and correction date 2026-09-14 are not new-search or external-full-text-reading dates.
Meta-analysis registration and list of included trials	Existence, availability and acquisition unverified; not read	Access not attempted	Not read	Unverified registration does not establish that registration was absent. Meta-analysis registration and included-trial registration are distinguished; no registration ID or location was created. The 12 unique RCTs and 13 SBP effects are wording from the retained report. Included trials, overlap, analysis-specific denominators, heterogeneity and detailed GRADE domains remain unverified. The material date 2026-10-06 concerns retained-summary review. Observations were applied after the conditions were frozen; historical records of later observation-wording and external-unread display changes were retained. The original verdict date 2026-09-08 and correction date 2026-09-14 are not new-search or external-full-text-reading dates.
Original supplementary material	Existence, availability and acquisition unverified; not read	Access not attempted	Not read	Supplement existence, exact location and original bytes are unverified. This does not establish supplement absence or actual access failure. The 12 unique RCTs and 13 SBP effects are wording from the retained report. Included trials, overlap, analysis-specific denominators, heterogeneity and detailed GRADE domains remain unverified. The material date 2026-10-06 concerns retained-summary review. Observations were applied after the conditions were frozen; historical records of later observation-wording and external-unread display changes were retained. The original verdict date 2026-09-08 and correction date 2026-09-14 are not new-search or external-full-text-reading dates.

Report counts versus independent study counts

The direct report and meta-analysis are not added as independent replications of the same question. The 12 unique RCTs and 13 SBP effects are wording from the retained meta-analysis; inclusion of the direct trial, overlap with other meta-analyses, unique trials and total participants remain unverified. The diabetes background reference is not added as a separate report.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which independent question does this table check?

Required materials and conditions: The comparison of between-group office SBP change in adults with metabolic syndrome not using antihypertensives: dried-powder 500 mg capsules at 2 g/day for 12 weeks versus starch placebo plus the same lifestyle counseling
Conditions for verification: Link the original Korean claim and both languages' population/intervention details to a single population, formulation, dose, 12-week period and placebo comparison, and record excluded extensions
Requirement and applicability: Required
Application exceptions: Meta-analysis averages, DBP, ambulatory blood pressure and endothelial function do not replace this selected question
Why this condition is needed: Needed to avoid combining ginger in general, other formulations, populations and endpoints into a single efficacy status
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N02 · Have direct and meta-analysis reports been kept from being double-counted as independent replications?

Required materials and conditions: The identities of the Rahimlou 2019 direct report and Karimi 2026 synthesis, the included-trial table, and whether the direct trial was included
Conditions for verification: Link the 2 retained reports and their bibliographies, distinguish 12 RCTs from 13 effects, and leave unique study and participant counts unconfirmed
Requirement and applicability: Required
Application exceptions: When included-trial tables and registration are unavailable, retain provisional report identities and unverified overlap
Why this condition is needed: Needed to avoid converting 2 reports and the meta-analysis's 12 RCTs and 13 effects into a count of unique replications
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N03 · What is the scope of the diabetes-only −1.62 mmHg reference without a bibliography?

Required materials and conditions: Check the value in the Korean/English counterview and counterpoint, and whether a separate bibliography, design, population, denominator and CI are linked
Conditions for verification: Retain −1.62 as background and record the limited fact that the current research/citation summaries contain only 2 reports without a separate identity for the diabetes analysis
Requirement and applicability: Required
Application exceptions: Retain the current wording without creating S03 for an unidentified meta-analysis
Why this condition is needed: Needed to avoid inventing an unidentified background reference as a newly verified report or direct replication
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N04 · Which materials were actually read, and which remain unread?

Required materials and conditions: The existence, access, acquisition, reading levels and links for the current retained summary and external index, DOI, PMC, registration and supplements
Conditions for verification: Link both local report summaries to the locations read and separately record unverified external material, unread status and access not attempted
Requirement and applicability: Required
Application exceptions: Access not attempted is not inaccessibility; do not create registration or supplement links without an exact location
Why this condition is needed: Needed to avoid treating the existence of a URL or PMCID as reading the original full text
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N05 · Which adults with metabolic syndrome were studied, and how far does applicability extend?

Required materials and conditions: Diagnosis, eligibility and exclusion criteria, age, setting, baseline SBP, medication use and characteristics by group
Conditions for verification: Record metabolic syndrome, exclusion of antihypertensive users and mean baseline about 121 together with unverified eligibility details
Requirement and applicability: Required
Application exceptions: Effects in mixed meta-analysis populations are not treated as effects in the same population as the direct trial
Why this condition is needed: Needed to avoid converting a population not using antihypertensives with baseline SBP about 121 into a population receiving hypertension treatment
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N06 · Which ginger formulation, route and dose were administered?

Required materials and conditions: Dried rhizome-powder 500 mg capsules, oral 2 g/day, assay-table units and batch information, and actual consumption
Conditions for verification: Link the formulation, route and dose in both languages to the original values and retain unclear assay units and unverified standardization/batch information
Requirement and applicability: Required
Application exceptions: Retain 2 g/day and 500 mg without calculating capsule counts or active-constituent amounts
Why this condition is needed: Needed to avoid interchanging powder with standardized extracts, essential oil or food
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N07 · What did the placebo and lifestyle counseling actually compare?

Required materials and conditions: The starch placebo, the content of identical lifestyle counseling, sensory matching, and actual treatment changes by group
Conditions for verification: Retain starch placebo and the same lifestyle counseling as the verified comparison, leaving detailed content and changes by group unverified
Requirement and applicability: Required
Application exceptions: Do not extend the statement of the same counseling to identical actual behavior, medication use or adherence
Why this condition is needed: Needed to avoid attributing differences in lifestyle intervention to ginger's own SBP effect
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N08 · Which outcome, unit, change and time point does 12-week SBP represent?

Required materials and conditions: Between-group change from baseline in 12-week office systolic blood pressure, mmHg, prespecified hierarchy and measurement conditions
Conditions for verification: Link selected 12-week office SBP change and the exclusion of other endpoints to the original locations, retaining unverified prespecification and measurement details
Requirement and applicability: Required
Application exceptions: The selected endpoint label does not establish actual prespecification as the 1st endpoint
Why this condition is needed: Needed to avoid combining final values, within-group change, DBP, ambulatory pressure and endothelial function as the same result
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N09 · Are the adjusted P value and raw change difference from rounded means the same estimate?

Required materials and conditions: The separate analyses, directions and CIs for adjusted between-group P=.165 and the raw −1.12 mmHg from rounded means
Conditions for verification: Retain adjusted P=.165, raw −1.12 and the unverified adjusted CI as separate attributions
Requirement and applicability: Required
Application exceptions: Do not recalculate raw −1.12 in this work or back-calculate an adjusted CI
Why this condition is needed: Needed to avoid converting a raw difference from rounded means into an adjusted effect or meta-analysis WMD
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N10 · Which denominators are represented by 38 randomized participants and 37 completers (19/18)?

Required materials and conditions: The total 38 randomized, 37 completers, arm mapping of 19/18, denominators randomized/analyzed/completing by group, and handling of missingness
Conditions for verification: Retain the original 38/37/19/18 and leave arm mapping, analysis denominators, ITT/PP and dropout reasons unverified
Requirement and applicability: Required
Application exceptions: Do not infer 19=ginger or 18=placebo, or derive dropout reasons from the 38 randomized participants
Why this condition is needed: Needed to avoid converting completer counts into randomized denominators by group or an ITT denominator
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N11 · Are the nonsignificant direct result and positive supportive meta-analysis signal both retained?

Required materials and conditions: Direct P=.165 and raw −1.12, and meta-analysis WMD −5.03/95% CI −8.49~−1.57/P=.004, low certainty and the diabetes background value −1.62
Conditions for verification: Attribute each value to its report/analysis and retain the unestablished direct result, low-certainty supportive signal and background reference without an identity together
Requirement and applicability: Required
Application exceptions: Numerical differences across populations, formulations or analyses are not automatically labeled conflicting data, effect 0 or equivalence
Why this condition is needed: Needed to avoid erasing the direct result with a favorable pooled estimate
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N12 · Which dates and preservation, search and correction scope support these statements?

Required materials and conditions: The original verdict date 2026-09-08, correction date 2026-09-14, actual current review date, retained record and unread external scope
Conditions for verification: Retain the complete current original record, all Korean/English content, axes and corrections, and disclose 0 new readings of full texts, abstracts or registration
Requirement and applicability: Required
Application exceptions: The verdict date is not a search cutoff or individual access date; an unperformed search does not mean 0 studies
Why this condition is needed: Needed to avoid inheriting past cross-checks, corrections or generic English wording as a current comprehensive literature check
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N13 · What do university support and the manufacturer's product name establish about funding and independence?

Required materials and conditions: The direct trial's funding, product provision, authors/institutions, employment, patents and COI details
Conditions for verification: Retain the original statement that university support and the product name are separate funding matters, and leave detailed support, author and institutional relationships unverified
Requirement and applicability: Supplementary; required for independence claims
Application exceptions: A product name alone does not establish company funding, and university support does not establish absence of all COI
Why this condition is needed: Needed to avoid combining university support and a manufacturer's product name as certification of independent funding or an independent team
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N14 · What level of verification is represented by the meta-analysis authors' declaration of no conflicts?

Required materials and conditions: Declared COI, funding and institutions of the meta-analysis, and funding/author relationships in the original trials
Conditions for verification: Retain the authors' declaration of no conflicts at its reported level, distinguishing it from detailed COI across original trials and verification of actually independent teams
Requirement and applicability: Supplementary; required for independence claims
Application exceptions: The authors' declaration alone is not extended to absence of bias, independent replication or absence of product support
Why this condition is needed: Needed to avoid converting review authors' declarations into independence of the 12 original trials
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N15 · How were randomization, concealment and blinding actually performed in the direct trial?

Required materials and conditions: The randomized, double-blind placebo-controlled design label, sequence generation, concealment and baseline balance
Conditions for verification: Retain the original randomized/double-blind/placebo design, leaving actual randomization, concealment, blinding targets and baseline balance unverified
Requirement and applicability: Required
Application exceptions: Do not assign crossover or cluster exceptions as not applicable when design details are unverified
Why this condition is needed: Needed to avoid verifying resolution of randomization issues from randomized and double-blind design labels alone
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N16 · Could adherence, concomitant treatment or changes in counseling be mixed with the effect?

Required materials and conditions: Actual consumption, discontinuation, lifestyle counseling, medications/rescue treatment, deviations and their handling by group
Conditions for verification: Record unverified adherence, changes by group and handling of deviations beyond the current comparator information
Requirement and applicability: Required
Application exceptions: Exclusion of antihypertensive users does not mean all treatment or behavior changes were absent during the trial
Why this condition is needed: Needed to avoid attributing differences in adherence and lifestyle changes to ginger
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N17 · Under which conditions and procedures was office SBP measured?

Required materials and conditions: Devices, rest, repeated measurements/averaging, assessors, blinding and assessment timing by group
Conditions for verification: Retain the 12-week office SBP label, leaving devices, assessment procedures, assessors and differences by group unverified
Requirement and applicability: Required
Application exceptions: A double-blind design alone does not establish all assessors and measurement methods
Why this condition is needed: Needed to distinguish measurement-procedure differences from actual between-group SBP differences
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N18 · Which population and intervention effect does the adjusted analysis estimate?

Required materials and conditions: Completer analysis, ITT/PP, adjustment covariates/model, estimand and analysis denominator
Conditions for verification: Retain the descriptions of 37 completers and an adjusted P value, leaving the exact analysis population, denominators by group, adjustment covariates and model unverified
Requirement and applicability: Required
Application exceptions: Do not fill in an unspecified analysis as ITT, PP or ANCOVA
Why this condition is needed: Needed to avoid combining a completer analysis and raw difference from rounded means as an adjusted assignment effect
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N19 · Can the adjusted interval and clinical importance of the direct effect be assessed?

Required materials and conditions: The direct trial's adjusted effect/95% CI, variance/denominators by group and a justified important SBP difference
Conditions for verification: Retain the unverified direct adjusted CI and clinical threshold, and do not use the meta-analysis's 95% CI as the direct trial's interval
Requirement and applicability: Required
Application exceptions: Do not arbitrarily set a common minimum sample size, trial count, duration or clinical threshold
Why this condition is needed: Needed to avoid judging direct-effect precision or importance sufficient from a P value, 38 participants or the meta-analysis CI alone
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N20 · Were prespecified SBP endpoints, analyses and registration compared with actual reporting?

Required materials and conditions: Original trial registration, protocol/statistical analysis plan, the hierarchy of 12-week SBP and analysis/multiplicity plans
Conditions for verification: Retain unverified prespecification and the unverified registration field, and disclose 0 current comparisons with registration/plans
Requirement and applicability: Required
Application exceptions: Unverified registration does not establish nonregistration or selective reporting
Why this condition is needed: Needed to avoid mistaking the selected endpoint label for a prespecified 1st endpoint designation
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N21 · How different are the supportive meta-analysis's unique trials, effects and conditions?

Required materials and conditions: The mapping of 12 unique RCTs and 13 SBP effects, populations/baseline pressure/formulations/doses/endpoint hierarchy, heterogeneity and detailed GRADE domains
Conditions for verification: Retain the original 12 RCTs/13 effects, different conditions, some 2nd blood-pressure endpoints and low certainty; leave trial-specific distributions and inclusion of the direct trial unverified
Requirement and applicability: Required
Application exceptions: Do not turn 13 effect sizes into 13 unique studies or add the direct trial as 1+12
Why this condition is needed: Needed to avoid presenting a positive pooled-average signal as independent replication of a single comparison
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N22 · Does the material answer questions about optimal dose, long-term persistence or subgroups?

Required materials and conditions: Direct dose comparisons, withdrawal/long-term follow-up, prespecified subgroups/interactions and the identity of the diabetes analysis
Conditions for verification: Treat the current 2 g/day and 12 weeks only as the trial specification, separating unverified direct evidence for optimal dose, persistence and subgroups
Requirement and applicability: Supplementary; required for extension claims
Application exceptions: Do not require every extension trial for the narrow 12-week SBP question
Why this condition is needed: Needed to avoid extending 2 g/day, 12 weeks and a meta-analysis title into optimal dose, persistence or diabetes effects
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N23 · Does an SBP change also answer questions about event prevention or medication replacement?

Required materials and conditions: Separate questions and direct evidence for the selected SBP outcome versus cardiovascular events, quality of life, mortality and antihypertensive replacement
Conditions for verification: Keep the office-SBP boundary and do not present event prevention or replacement as currently verified results
Requirement and applicability: Supplementary; required for clinical extension claims
Application exceptions: Because SBP itself is the question, absence of event trials does not remove direct SBP reporting
Why this condition is needed: Needed to avoid converting a blood-pressure signal into cardiovascular-event prevention or treatment replacement
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N24 · What level of harm verification is represented by the caution in the efficacy summary?

Required materials and conditions: Actual adverse events, collection methods, denominators, discontinuations and the original caution for the same population, powder and period
Conditions for verification: Retain dizziness, hypotension and interaction cautions as the original narrative, separately showing unverified observed events, frequencies and discontinuations
Requirement and applicability: Supplementary; required for safety claims
Application exceptions: Unverified harm information does not remove the original SBP report or justify filling in safety
Why this condition is needed: Needed to avoid converting the existence of an efficacy/meta-analysis summary into verified safety
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N25 · Are dizziness and hypotension actual observed events or cautionary statements?

Required materials and conditions: Trial event definitions/adjudication, systematic or spontaneous collection, severity and discontinuation records
Conditions for verification: Separate the original caution wording from unverified current information on adverse events and their collection
Requirement and applicability: Supplementary; required for harm questions
Application exceptions: Retain the original caution list without inventing observed events
Why this condition is needed: Needed to avoid converting recommendations into actual events or confirmed diagnoses
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N26 · Is the temporal relationship between exposure and actual harm verified?

Required materials and conditions: Starting 2 g/day, the 12-week period, event onset/recovery, discontinuation/re-exposure and observation periods
Conditions for verification: Distinguish the 12-week treatment specification from unverified timing of actual events, discontinuation and re-exposure
Requirement and applicability: Supplementary; required for harm questions
Application exceptions: Do not fill in temporal order or causality without discontinuation/re-exposure records
Why this condition is needed: Needed to avoid inferring harm-onset or recovery timing from treatment duration alone
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N27 · Against which comparator were harms actually compared?

Required materials and conditions: Actual adverse events and comparative estimates involving placebo, background conditions and concomitant medications
Conditions for verification: Record the starch-placebo/same-counseling comparison separately from unverified comparative harms by group
Requirement and applicability: Supplementary; required for comparative harm claims
Application exceptions: When an efficacy comparator exists but harm-event tables do not, leave comparative harms unverified
Why this condition is needed: Needed to avoid converting an efficacy comparison with starch placebo into observed comparative harm results
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N28 · Are denominators and exposure time available for harm frequency?

Required materials and conditions: Numbers exposed or in the safety analysis, people with events versus event counts, and exposure/follow-up time
Conditions for verification: Do not reuse randomized/completer efficacy denominators as safety denominators; retain unverified event, exposure and follow-up denominators
Requirement and applicability: Supplementary; required for incidence claims
Application exceptions: Do not calculate 0 events, 0% or a denominator from a current summary without events
Why this condition is needed: Needed to avoid converting 38 randomized participants, 37 completers or the meta-analysis's 12 trials into an adverse-event incidence denominator
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N29 · What alternative explanations involve concomitant medications, baseline conditions or lifestyle changes?

Required materials and conditions: Exclusion of antihypertensive users, other medications/diseases, lifestyle counseling, dose and their relationship to actual harms
Conditions for verification: Distinguish medication-user exclusion in the direct trial from the general antihypertensive-combination caution, retaining unverified other concomitant exposures and alternatives
Requirement and applicability: Supplementary; required for causal harm claims
Application exceptions: Do not describe an undocumented concomitant exposure as absent
Why this condition is needed: Needed to avoid converting an interaction caution into direct verification of harm from combined use in this trial
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N30 · What is known about harm collection, reporting and loss to follow-up?

Required materials and conditions: Collection of all adverse events, selection/recall/detection, missing safety follow-up and reasons for discontinuation/dropout
Conditions for verification: State that the current retained summary cannot establish collection, selection or missingness, without estimating the extent of actual missing harms
Requirement and applicability: Supplementary; required for harm questions
Application exceptions: Because the external full text was not read, nonreporting of adverse events in the original article is not established
Why this condition is needed: Needed to avoid converting omissions in a summary or a completer analysis into absence of harms
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N31 · Are the same harm events linked in other independent material?

Required materials and conditions: Identities of unique events/study families, reports and repeat citations, matched exposure/events and regulatory material
Conditions for verification: Retain the limited fact that independent harm cases/families are unverified in both stored efficacy reports, without inventing replication counts
Requirement and applicability: Supplementary; required for repeated harm claims
Application exceptions: Do not search for new safety material here or convert unverified status into 0 harm studies
Why this condition is needed: Needed to avoid counting meta-analysis, caution wording and Korean/English repeat citations as independent repetitions of events
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N32 · Does the material address long-term or rare harms and other vulnerable populations?

Required materials and conditions: Exposure beyond 12 weeks and separate direct material on rare events, medication users, pregnancy/baseline risk and interactions
Conditions for verification: Separate the current population/12-week period from unverified long-term, combined-medication and special-population safety
Requirement and applicability: Supplementary; required for overall safety claims
Application exceptions: Do not require every long-term or rare-harm trial for the narrow SBP question
Why this condition is needed: Needed to avoid extending short-term material in a limited population not using antihypertensives into safety for everyone
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N33 · Does the current caution wording describe a signal, incidence or causality?

Required materials and conditions: The reporting level of the original caution, actual design/events/denominators/timing/alternatives and possible interpretation
Conditions for verification: Retain the original caution as a limited statement, without presenting actual causal effects, frequencies or safety certification as verified in the current trial
Requirement and applicability: Supplementary; required for causal harm or safety claims
Application exceptions: Do not create personal dosing instructions or a new efficacy/safety judgment
Why this condition is needed: Needed to avoid promoting a general caution into harm causality, incidence or a new safety grade
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

What the statuses mean

Partly verified: Partial information from the stored summary is linked; detailed originals and content review remain incomplete.
Unverified: Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.
Review incomplete: Review of existing content remains incomplete.
Met: The selected condition for material, identity or preservation was verified; this does not establish efficacy success or independent clinical validation.
Not reported: Unreported within material actually read. Unread external material is not relabeled as unreported.
Inaccessible: This means actual access failure. External access was not attempted in this work, so this state was not assigned.
Not applicable: Used only with an application exception and reason based on the question scope.
Conflicting data: This requires actual comparison of materials; no new conflict judgment was made in this work.
Insufficient evidence for the conditions: This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade.

Change history

2026-10-25 · Public page/material version 1.0

The public view and materials were prepared from the existing 33 items. No new clinical search, verification-state change or scoring was performed.

The stored-material review date (2026-10-06) and original evidence cut-off (2026-09-08) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which independent question does this table check?

Current findings: The original claim concerns office systolic blood-pressure reduction in adults with metabolic syndrome. Both sets of population/intervention details connect metabolic syndrome, exclusion of antihypertensive users, mean baseline SBP about 121, dried-powder 500 mg capsules at 2 g/day for 12 weeks, starch placebo plus the same lifestyle counseling, and between-group office SBP change.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: This verifies the link between the original record and the selected narrow question. It does not establish a reduction, full-text reading or new efficacy certification.
Reason for missing information: This verifies the link between the original record and the selected narrow question. It does not establish a reduction, full-text reading or new efficacy certification.
Required materials and conditions: The comparison of between-group office SBP change in adults with metabolic syndrome not using antihypertensives: dried-powder 500 mg capsules at 2 g/day for 12 weeks versus starch placebo plus the same lifestyle counseling
Materials to obtain first: If the boundary changes, an original report specifying the population, endpoint, formulation, comparison and timing
Further research: Material needed: If the boundary changes, an original report specifying the population, endpoint, formulation, comparison and timing. This records needed materials; no new research was executed.
Remaining uncertainty: This verifies the link between the original record and the selected narrow question. It does not establish a reduction, full-text reading or new efficacy certification.
Conditions for verification: Link the original Korean claim and both languages' population/intervention details to a single population, formulation, dose, 12-week period and placebo comparison, and record excluded extensions
Why this condition is needed: Needed to avoid combining ginger in general, other formulations, populations and endpoints into a single efficacy status
Application exceptions: Meta-analysis averages, DBP, ambulatory blood pressure and endothelial function do not replace this selected question
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N02 · Have direct and meta-analysis reports been kept from being double-counted as independent replications?

Current findings: The current research and citation summaries each contain 2 entries. The Rahimlou 2019 direct report and Karimi 2026 meta-analysis are distinguished. The meta-analysis reports 12 unique RCTs and 13 SBP effect sizes; inclusion of S01 and the list of original trial families are unavailable.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The bibliographic identities of both reports are retained, but the mapping and overlap of 12 original trials and 13 effects were not compared. The number of unique independent trials and total participants remain unconfirmed.
Reason for missing information: The bibliographic identities of both reports are retained, but the mapping and overlap of 12 original trials and 13 effects were not compared. The number of unique independent trials and total participants remain unconfirmed.
Required materials and conditions: The identities of the Rahimlou 2019 direct report and Karimi 2026 synthesis, the included-trial table, and whether the direct trial was included
Materials to obtain first: The meta-analysis included-trial/effect mapping table, registration, and a list of related direct-trial reports
Further research: Material needed: The meta-analysis included-trial/effect mapping table, registration, and a list of related direct-trial reports. This records needed materials; no new research was executed.
Remaining uncertainty: The bibliographic identities of both reports are retained, but the mapping and overlap of 12 original trials and 13 effects were not compared. The number of unique independent trials and total participants remain unconfirmed.
Conditions for verification: Link the 2 retained reports and their bibliographies, distinguish 12 RCTs from 13 effects, and leave unique study and participant counts unconfirmed
Why this condition is needed: Needed to avoid converting 2 reports and the meta-analysis's 12 RCTs and 13 effects into a count of unique replications
Application exceptions: When included-trial tables and registration are unavailable, retain provisional report identities and unverified overlap
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N03 · What is the scope of the diabetes-only −1.62 mmHg reference without a bibliography?

Current findings: The Korean/English counterview and counterpoint mention −1.62 mmHg from a diabetes-only 2026 analysis. The current 2 research/citation entries identify the direct trial and broader meta-analysis; a separate bibliography, denominator, CI and P value for this diabetes analysis are not linked.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The limited identity and attribution boundary of the retained wording was verified. It is neither deleted nor invented as S03 or a new trial family; this does not mean the study is absent from all literature.
Reason for missing information: The limited identity and attribution boundary of the retained wording was verified. It is neither deleted nor invented as S03 or a new trial family; this does not mean the study is absent from all literature.
Required materials and conditions: Check the value in the Korean/English counterview and counterpoint, and whether a separate bibliography, design, population, denominator and CI are linked
Materials to obtain first: The actual bibliography, included-trial table and original result location for the diabetes-only analysis
Further research: Material needed: The actual bibliography, included-trial table and original result location for the diabetes-only analysis. This records needed materials; no new research was executed.
Remaining uncertainty: The limited identity and attribution boundary of the retained wording was verified. It is neither deleted nor invented as S03 or a new trial family; this does not mean the study is absent from all literature.
Conditions for verification: Retain −1.62 as background and record the limited fact that the current research/citation summaries contain only 2 reports without a separate identity for the diabetes analysis
Why this condition is needed: Needed to avoid inventing an unidentified background reference as a newly verified report or direct replication
Application exceptions: Retain the current wording without creating S03 for an unidentified meta-analysis
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N04 · Which materials were actually read, and which remain unread?

Current findings: Both report summaries, Korean/English evidence and bibliographies, and all original values in the retained record were actually read. Each PubMed URL and bibliographic DOI/PMCID is a retained entry point. External abstracts, full texts, PMC material, registration and supplements were not accessed, acquired or read in this work.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Actual acquisition and reading apply only to locally retained summaries. Current external existence and successful responses remain unverified; they are not labeled as access failures or acquired full texts.
Reason for missing information: Actual acquisition and reading apply only to locally retained summaries. Current external existence and successful responses remain unverified; they are not labeled as access failures or acquired full texts.
Required materials and conditions: The existence, access, acquisition, reading levels and links for the current retained summary and external index, DOI, PMC, registration and supplements
Materials to obtain first: Actual responses, acquired original bytes, versions, reading dates and exact links for each material
Further research: Material needed: Actual responses, acquired original bytes, versions, reading dates and exact links for each material. This records needed materials; no new research was executed.
Remaining uncertainty: Actual acquisition and reading apply only to locally retained summaries. Current external existence and successful responses remain unverified; they are not labeled as access failures or acquired full texts.
Conditions for verification: Link both local report summaries to the locations read and separately record unverified external material, unread status and access not attempted
Why this condition is needed: Needed to avoid treating the existence of a URL or PMCID as reading the original full text
Application exceptions: Access not attempted is not inaccessibility; do not create registration or supplement links without an exact location
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N05 · Which adults with metabolic syndrome were studied, and how far does applicability extend?

Current findings: The population details in both languages specify adults with metabolic syndrome, mean baseline SBP about 121 mmHg, and exclusion of antihypertensive users. Differences in meta-analysis populations and baseline blood pressure appear in the rationale, but details of diagnosis, age, recruitment and baseline distributions by group in the direct trial remain unverified.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The stated population characteristics were verified, but applicability to people treated for hypertension, representativeness and detailed eligibility criteria were not newly verified.
Reason for missing information: The stated population characteristics were verified, but applicability to people treated for hypertension, representativeness and detailed eligibility criteria were not newly verified.
Required materials and conditions: Diagnosis, eligibility and exclusion criteria, age, setting, baseline SBP, medication use and characteristics by group
Materials to obtain first: The direct trial's eligibility/exclusion criteria and baseline table by group, and meta-analysis results by population
Further research: Material needed: The direct trial's eligibility/exclusion criteria and baseline table by group, and meta-analysis results by population. This records needed materials; no new research was executed.
Remaining uncertainty: The stated population characteristics were verified, but applicability to people treated for hypertension, representativeness and detailed eligibility criteria were not newly verified.
Conditions for verification: Record metabolic syndrome, exclusion of antihypertensive users and mean baseline about 121 together with unverified eligibility details
Why this condition is needed: Needed to avoid converting a population not using antihypertensives with baseline SBP about 121 into a population receiving hypertension treatment
Application exceptions: Effects in mixed meta-analysis populations are not treated as effects in the same population as the direct trial
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N06 · Which ginger formulation, route and dose were administered?

Current findings: The original material, formulation, route and dose are Zingiber officinale Roscoe rhizome; dried ginger-powder 500 mg capsules; unclear assay-table units; oral administration; and 2 g/day. Standardized extracts, essential oil and food are distinguished in the product information.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The nominal powder formulation and dose are retained, but assay units, standardization, batch information and actual adherence-adjusted intake are unverified. Capsule counts and active-constituent amounts were not calculated.
Reason for missing information: The nominal powder formulation and dose are retained, but assay units, standardization, batch information and actual adherence-adjusted intake are unverified. Capsule counts and active-constituent amounts were not calculated.
Required materials and conditions: Dried rhizome-powder 500 mg capsules, oral 2 g/day, assay-table units and batch information, and actual consumption
Materials to obtain first: Product specifications, assay-table units, batch documentation and actual administration records
Further research: Material needed: Product specifications, assay-table units, batch documentation and actual administration records. This records needed materials; no new research was executed.
Remaining uncertainty: The nominal powder formulation and dose are retained, but assay units, standardization, batch information and actual adherence-adjusted intake are unverified. Capsule counts and active-constituent amounts were not calculated.
Conditions for verification: Link the formulation, route and dose in both languages to the original values and retain unclear assay units and unverified standardization/batch information
Why this condition is needed: Needed to avoid interchanging powder with standardized extracts, essential oil or food
Application exceptions: Retain 2 g/day and 500 mg without calculating capsule counts or active-constituent amounts
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N07 · What did the placebo and lifestyle counseling actually compare?

Current findings: The recorded comparator is starch placebo plus the same lifestyle counseling, as also stated in English. The actual content of counseling, sensory matching of the placebo, and treatment or lifestyle changes by group could not be verified in the current retained summary.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The placebo/counseling comparison is verified, but this does not establish that all actual behavior and medication changes were identical.
Reason for missing information: The placebo/counseling comparison is verified, but this does not establish that all actual behavior and medication changes were identical.
Required materials and conditions: The starch placebo, the content of identical lifestyle counseling, sensory matching, and actual treatment changes by group
Materials to obtain first: Placebo composition, counseling procedures, and records of concomitant interventions and changes by group
Further research: Material needed: Placebo composition, counseling procedures, and records of concomitant interventions and changes by group. This records needed materials; no new research was executed.
Remaining uncertainty: The placebo/counseling comparison is verified, but this does not establish that all actual behavior and medication changes were identical.
Conditions for verification: Retain starch placebo and the same lifestyle counseling as the verified comparison, leaving detailed content and changes by group unverified
Why this condition is needed: Needed to avoid attributing differences in lifestyle intervention to ginger's own SBP effect
Application exceptions: Do not extend the statement of the same counseling to identical actual behavior, medication use or adherence
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N08 · Which outcome, unit, change and time point does 12-week SBP represent?

Current findings: The selected endpoint is between-group change in office SBP at 12 weeks, and the duration is 12 weeks of treatment. The scope note limits the question to office SBP; the reader answer states that matching SBP prespecification as the 1st endpoint is unclear.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Attribution to 12-week office SBP change is verified, but the actual prespecified hierarchy, measurement method and assessment schedule are unverified. DBP, ambulatory pressure and endothelial function do not replace it.
Reason for missing information: Attribution to 12-week office SBP change is verified, but the actual prespecified hierarchy, measurement method and assessment schedule are unverified. DBP, ambulatory pressure and endothelial function do not replace it.
Required materials and conditions: Between-group change from baseline in 12-week office systolic blood pressure, mmHg, prespecified hierarchy and measurement conditions
Materials to obtain first: The 12-week result table, assessment method, and SBP hierarchy in the protocol/statistical analysis plan
Further research: Material needed: The 12-week result table, assessment method, and SBP hierarchy in the protocol/statistical analysis plan. This records needed materials; no new research was executed.
Remaining uncertainty: Attribution to 12-week office SBP change is verified, but the actual prespecified hierarchy, measurement method and assessment schedule are unverified. DBP, ambulatory pressure and endothelial function do not replace it.
Conditions for verification: Link selected 12-week office SBP change and the exclusion of other endpoints to the original locations, retaining unverified prespecification and measurement details
Why this condition is needed: Needed to avoid combining final values, within-group change, DBP, ambulatory pressure and endothelial function as the same result
Application exceptions: The selected endpoint label does not establish actual prespecification as the 1st endpoint
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N09 · Are the adjusted P value and raw change difference from rounded means the same estimate?

Current findings: The direct result is retained as adjusted between-group P=.165; raw change difference from rounded means −1.12 mmHg; adjusted CI unverified. The reader answer's adjusted P=.165 and the raw rounded change difference of −1.12 mmHg are each preserved.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The distinction between the P value and raw difference is retained, but the adjusted effect/CI, exact raw table/model and analysis denominators by group are unverified. They were neither substituted as adjusted values nor recalculated.
Reason for missing information: The distinction between the P value and raw difference is retained, but the adjusted effect/CI, exact raw table/model and analysis denominators by group are unverified. They were neither substituted as adjusted values nor recalculated.
Required materials and conditions: The separate analyses, directions and CIs for adjusted between-group P=.165 and the raw −1.12 mmHg from rounded means
Materials to obtain first: The exact raw result table, adjusted estimate/model/covariates, CI and denominators by group
Further research: Material needed: The exact raw result table, adjusted estimate/model/covariates, CI and denominators by group. This records needed materials; no new research was executed.
Remaining uncertainty: The distinction between the P value and raw difference is retained, but the adjusted effect/CI, exact raw table/model and analysis denominators by group are unverified. They were neither substituted as adjusted values nor recalculated.
Conditions for verification: Retain adjusted P=.165, raw −1.12 and the unverified adjusted CI as separate attributions
Why this condition is needed: Needed to avoid converting a raw difference from rounded means into an adjusted effect or meta-analysis WMD
Application exceptions: Do not recalculate raw −1.12 in this work or back-calculate an adjusted CI
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N10 · Which denominators are represented by 38 randomized participants and 37 completers (19/18)?

Current findings: The retained direct-trial denominator is 38 randomized participants and 37 completers (19/18). The 38 are described as randomized and the 37 as completers; the ginger/placebo arm mapping of 19/18 is not explicitly stated in the original record.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Do not infer that 19 means ginger and 18 means placebo. Data on randomized/analyzed/completing denominators by group, ITT/PP, reasons for dropout and their handling are unavailable, so efficacy and safety denominators cannot be confirmed.
Reason for missing information: Do not infer that 19 means ginger and 18 means placebo. Data on randomized/analyzed/completing denominators by group, ITT/PP, reasons for dropout and their handling are unavailable, so efficacy and safety denominators cannot be confirmed.
Required materials and conditions: The total 38 randomized, 37 completers, arm mapping of 19/18, denominators randomized/analyzed/completing by group, and handling of missingness
Materials to obtain first: Participant flow by group, completion/analysis tables, missing-data handling and the statistical analysis plan
Further research: Material needed: Participant flow by group, completion/analysis tables, missing-data handling and the statistical analysis plan. This records needed materials; no new research was executed.
Remaining uncertainty: Do not infer that 19 means ginger and 18 means placebo. Data on randomized/analyzed/completing denominators by group, ITT/PP, reasons for dropout and their handling are unavailable, so efficacy and safety denominators cannot be confirmed.
Conditions for verification: Retain the original 38/37/19/18 and leave arm mapping, analysis denominators, ITT/PP and dropout reasons unverified
Why this condition is needed: Needed to avoid converting completer counts into randomized denominators by group or an ITT denominator
Application exceptions: Do not infer 19=ginger or 18=placebo, or derive dropout reasons from the 38 randomized participants
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N11 · Are the nonsignificant direct result and positive supportive meta-analysis signal both retained?

Current findings: The original values are retained separately: direct adjusted between-group P=.165; raw change difference from rounded means −1.12 mmHg; adjusted CI unverified; and meta-analysis WMD −5.03 mmHg, 95% CI −8.49~−1.57, P=.004, with low certainty. The reader answer states that the direct result was not established and E0 was not assigned because prespecification is unclear; the key explanation and rationale limit the pooled signal by low certainty and heterogeneity. The diabetes −1.62 reference is background without a linked identity.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The favorable meta-analysis value did not erase the nonsignificant direct result. Numerical differences across populations or analyses were not converted into conflicting data under the same comparison, effect 0 or equivalence.
Reason for missing information: The favorable meta-analysis value did not erase the nonsignificant direct result. Numerical differences across populations or analyses were not converted into conflicting data under the same comparison, effect 0 or equivalence.
Required materials and conditions: Direct P=.165 and raw −1.12, and meta-analysis WMD −5.03/95% CI −8.49~−1.57/P=.004, low certainty and the diabetes background value −1.62
Materials to obtain first: Exact result tables by report, included trials and heterogeneity in the meta-analysis, and the identity of the diabetes analysis
Further research: Material needed: Exact result tables by report, included trials and heterogeneity in the meta-analysis, and the identity of the diabetes analysis. This records needed materials; no new research was executed.
Remaining uncertainty: The favorable meta-analysis value did not erase the nonsignificant direct result. Numerical differences across populations or analyses were not converted into conflicting data under the same comparison, effect 0 or equivalence.
Conditions for verification: Attribute each value to its report/analysis and retain the unestablished direct result, low-certainty supportive signal and background reference without an identity together
Why this condition is needed: Needed to avoid erasing the direct result with a favorable pooled estimate
Application exceptions: Numerical differences across populations, formulations or analyses are not automatically labeled conflicting data, effect 0 or equivalence
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N12 · Which dates and preservation, search and correction scope support these statements?

Current findings: The original verdict date is 2026-09-08, and the correction record describes the 2026-09-14 English placeholder correction, C→C. The actual source, Korean/English content, generic English evidence wording, axes, empty subclaims, deliberation and URLs were retained. This work converts the retained summary; new external full-text, abstract, registration, correction and retraction queries total 0.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The review date concerns the current reading event; the original verdict date concerns historical record review. The historical search cutoff, individual access dates and complete current literature status were not retrospectively verified.
Reason for missing information: The review date concerns the current reading event; the original verdict date concerns historical record review. The historical search cutoff, individual access dates and complete current literature status were not retrospectively verified.
Required materials and conditions: The original verdict date 2026-09-08, correction date 2026-09-14, actual current review date, retained record and unread external scope
Materials to obtain first: Historical search/access records and original publication, correction and retraction records
Further research: Material needed: Historical search/access records and original publication, correction and retraction records. This records needed materials; no new research was executed.
Remaining uncertainty: The review date concerns the current reading event; the original verdict date concerns historical record review. The historical search cutoff, individual access dates and complete current literature status were not retrospectively verified.
Conditions for verification: Retain the complete current original record, all Korean/English content, axes and corrections, and disclose 0 new readings of full texts, abstracts or registration
Why this condition is needed: Needed to avoid inheriting past cross-checks, corrections or generic English wording as a current comprehensive literature check
Application exceptions: The verdict date is not a search cutoff or individual access date; an unperformed search does not mean 0 studies
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N13 · What do university support and the manufacturer's product name establish about funding and independence?

Current findings: The direct-trial funding field states university support, with the manufacturer's product name separate from funding. The rationale's description of university support as a strength and the I2 axis are retained as history. Product provision, author employment/patents, detailed COI and institutional relationships are not established in this retained summary.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Only the statements of university support and the distinction between the manufacturer's product name and funding were verified. Company funding, independent teams or absence of all COI are not confirmed.
Reason for missing information: Only the statements of university support and the distinction between the manufacturer's product name and funding were verified. Company funding, independent teams or absence of all COI are not confirmed.
Required materials and conditions: The direct trial's funding, product provision, authors/institutions, employment, patents and COI details
Materials to obtain first: Original funding, acknowledgment and COI locations, product-support documentation and author relationships for the direct trial
Further research: Material needed: Original funding, acknowledgment and COI locations, product-support documentation and author relationships for the direct trial. This records needed materials; no new research was executed.
Remaining uncertainty: Only the statements of university support and the distinction between the manufacturer's product name and funding were verified. Company funding, independent teams or absence of all COI are not confirmed.
Conditions for verification: Retain the original statement that university support and the product name are separate funding matters, and leave detailed support, author and institutional relationships unverified
Why this condition is needed: Needed to avoid combining university support and a manufacturer's product name as certification of independent funding or an independent team
Application exceptions: A product name alone does not establish company funding, and university support does not establish absence of all COI
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N14 · What level of verification is represented by the meta-analysis authors' declaration of no conflicts?

Current findings: The retained meta-analysis funding field states that the authors declared no conflicts of interest. The current record provides only the meta-analysis declaration; it does not provide funding, product/author relationships or institutional families for each included trial.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The meta-analysis authors' declaration is not used to verify independence, absence of bias or absence of product support across all 12 original trials.
Reason for missing information: The meta-analysis authors' declaration is not used to verify independence, absence of bias or absence of product support across all 12 original trials.
Required materials and conditions: Declared COI, funding and institutions of the meta-analysis, and funding/author relationships in the original trials
Materials to obtain first: Original meta-analysis COI/funding locations and a table of funding and institutions by included trial
Further research: Material needed: Original meta-analysis COI/funding locations and a table of funding and institutions by included trial. This records needed materials; no new research was executed.
Remaining uncertainty: The meta-analysis authors' declaration is not used to verify independence, absence of bias or absence of product support across all 12 original trials.
Conditions for verification: Retain the authors' declaration of no conflicts at its reported level, distinguishing it from detailed COI across original trials and verification of actually independent teams
Why this condition is needed: Needed to avoid converting review authors' declarations into independence of the 12 original trials
Application exceptions: The authors' declaration alone is not extended to absence of bias, independent replication or absence of product support
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S02

N15 · How were randomization, concealment and blinding actually performed in the direct trial?

Current findings: The direct design is described as randomized, double-blind and placebo-controlled in both languages. Sequence generation, concealment, who was blinded, blinding success and baseline balance by group remain unverified.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The retained design label was verified. It does not certify that randomization, confounding or measurement issues were resolved, and unverified design details are not labeled not applicable.
Reason for missing information: The retained design label was verified. It does not certify that randomization, confounding or measurement issues were resolved, and unverified design details are not labeled not applicable.
Required materials and conditions: The randomized, double-blind placebo-controlled design label, sequence generation, concealment and baseline balance
Materials to obtain first: Original methods, baseline tables by group, and randomization, concealment and blinding procedures
Further research: Material needed: Original methods, baseline tables by group, and randomization, concealment and blinding procedures. This records needed materials; no new research was executed.
Remaining uncertainty: The retained design label was verified. It does not certify that randomization, confounding or measurement issues were resolved, and unverified design details are not labeled not applicable.
Conditions for verification: Retain the original randomized/double-blind/placebo design, leaving actual randomization, concealment, blinding targets and baseline balance unverified
Why this condition is needed: Needed to avoid verifying resolution of randomization issues from randomized and double-blind design labels alone
Application exceptions: Do not assign crossover or cluster exceptions as not applicable when design details are unverified
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N16 · Could adherence, concomitant treatment or changes in counseling be mixed with the effect?

Current findings: The population/intervention details specify the same lifestyle counseling, starch placebo and exclusion of antihypertensive users. The retained summary lacks actual adherence, discontinuation, counseling implementation, concomitant medications/rescue treatment, changes by group and their handling.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Original material needed to verify the influence of actual deviations and treatment changes beyond the comparison specification on SBP analysis was not read. Absence of changes is not assumed.
Reason for missing information: Original material needed to verify the influence of actual deviations and treatment changes beyond the comparison specification on SBP analysis was not read. Absence of changes is not assumed.
Required materials and conditions: Actual consumption, discontinuation, lifestyle counseling, medications/rescue treatment, deviations and their handling by group
Materials to obtain first: Consumption/counseling, concomitant medication, rescue-treatment, deviation and analysis-handling records
Further research: Material needed: Consumption/counseling, concomitant medication, rescue-treatment, deviation and analysis-handling records. This records needed materials; no new research was executed.
Remaining uncertainty: Original material needed to verify the influence of actual deviations and treatment changes beyond the comparison specification on SBP analysis was not read. Absence of changes is not assumed.
Conditions for verification: Record unverified adherence, changes by group and handling of deviations beyond the current comparator information
Why this condition is needed: Needed to avoid attributing differences in adherence and lifestyle changes to ginger
Application exceptions: Exclusion of antihypertensive users does not mean all treatment or behavior changes were absent during the trial
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N17 · Under which conditions and procedures was office SBP measured?

Current findings: The retained endpoint and population/intervention details specify 12-week office SBP, but do not provide devices, rest, repeated measurements/averaging, assessors or measurement timing by group. The double-blind label is not a specific assessor procedure.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Material establishing actual measurement conditions and differences by group for the selected office SBP remains unread. An objective endpoint does not remove measurement limitations.
Reason for missing information: Material establishing actual measurement conditions and differences by group for the selected office SBP remains unread. An objective endpoint does not remove measurement limitations.
Required materials and conditions: Devices, rest, repeated measurements/averaging, assessors, blinding and assessment timing by group
Materials to obtain first: Original measurement procedures and assessment schedules, including error and missing-measurement records
Further research: Material needed: Original measurement procedures and assessment schedules, including error and missing-measurement records. This records needed materials; no new research was executed.
Remaining uncertainty: Material establishing actual measurement conditions and differences by group for the selected office SBP remains unread. An objective endpoint does not remove measurement limitations.
Conditions for verification: Retain the 12-week office SBP label, leaving devices, assessment procedures, assessors and differences by group unverified
Why this condition is needed: Needed to distinguish measurement-procedure differences from actual between-group SBP differences
Application exceptions: A double-blind design alone does not establish all assessors and measurement methods
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N18 · Which population and intervention effect does the adjusted analysis estimate?

Current findings: The reader answer and rationale describe a 37-completer trial, small-sample/completer-analysis limitations and adjusted P=.165. The original denominator is 38 randomized and 37 completing; the result's −1.12 is a raw change difference from rounded means.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The completer-analysis and adjusted-P descriptions are verified, but exact analysis denominators/populations, ITT/PP, estimands, covariates/models and missing-data handling are unverified. They are not filled in as ANCOVA or ITT.
Reason for missing information: The completer-analysis and adjusted-P descriptions are verified, but exact analysis denominators/populations, ITT/PP, estimands, covariates/models and missing-data handling are unverified. They are not filled in as ANCOVA or ITT.
Required materials and conditions: Completer analysis, ITT/PP, adjustment covariates/model, estimand and analysis denominator
Materials to obtain first: Exact analysis tables, statistical analysis plan, model, analysis population and missing-data handling
Further research: Material needed: Exact analysis tables, statistical analysis plan, model, analysis population and missing-data handling. This records needed materials; no new research was executed.
Remaining uncertainty: The completer-analysis and adjusted-P descriptions are verified, but exact analysis denominators/populations, ITT/PP, estimands, covariates/models and missing-data handling are unverified. They are not filled in as ANCOVA or ITT.
Conditions for verification: Retain the descriptions of 37 completers and an adjusted P value, leaving the exact analysis population, denominators by group, adjustment covariates and model unverified
Why this condition is needed: Needed to avoid combining a completer analysis and raw difference from rounded means as an adjusted assignment effect
Application exceptions: Do not fill in an unspecified analysis as ITT, PP or ANCOVA
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N19 · Can the adjusted interval and clinical importance of the direct effect be assessed?

Current findings: The direct result and rationale explicitly leave the adjusted CI and clinical threshold unverified. The meta-analysis's 95% CI −8.49~−1.57 belongs to a separate pooled WMD and is not the direct trial's adjusted interval.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The relationship between the direct effect's adjusted interval and a justified important SBP difference was not verified. P values, sample size and the meta-analysis CI do not establish sufficiency.
Reason for missing information: The relationship between the direct effect's adjusted interval and a justified important SBP difference was not verified. P values, sample size and the meta-analysis CI do not establish sufficiency.
Required materials and conditions: The direct trial's adjusted effect/95% CI, variance/denominators by group and a justified important SBP difference
Materials to obtain first: The direct adjusted CI, estimate/variance and basis for clinical importance
Further research: Material needed: The direct adjusted CI, estimate/variance and basis for clinical importance. This records needed materials; no new research was executed.
Remaining uncertainty: The relationship between the direct effect's adjusted interval and a justified important SBP difference was not verified. P values, sample size and the meta-analysis CI do not establish sufficiency.
Conditions for verification: Retain the unverified direct adjusted CI and clinical threshold, and do not use the meta-analysis's 95% CI as the direct trial's interval
Why this condition is needed: Needed to avoid judging direct-effect precision or importance sufficient from a P value, 38 participants or the meta-analysis CI alone
Application exceptions: Do not arbitrarily set a common minimum sample size, trial count, duration or clinical threshold
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N20 · Were prespecified SBP endpoints, analyses and registration compared with actual reporting?

Current findings: The direct-trial registration field is unverified, and the evidence weight describes the principal direct trial with unverified prespecification. The Korean/English reader answers state that matching SBP prespecification is unclear. Registration, the protocol/statistical analysis plan and change history were not read in this work.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The selected endpoint label is distinguished from actual confirmation of the prespecified 1st endpoint/statistical analysis plan. Unverified registration does not establish nonregistration or selective reporting, and the original EX is not changed to E0.
Reason for missing information: The selected endpoint label is distinguished from actual confirmation of the prespecified 1st endpoint/statistical analysis plan. Unverified registration does not establish nonregistration or selective reporting, and the original EX is not changed to E0.
Required materials and conditions: Original trial registration, protocol/statistical analysis plan, the hierarchy of 12-week SBP and analysis/multiplicity plans
Materials to obtain first: Actual original-trial registration, protocol/statistical analysis plan, change history and the corresponding result tables
Further research: Material needed: Actual original-trial registration, protocol/statistical analysis plan, change history and the corresponding result tables. This records needed materials; no new research was executed.
Remaining uncertainty: The selected endpoint label is distinguished from actual confirmation of the prespecified 1st endpoint/statistical analysis plan. Unverified registration does not establish nonregistration or selective reporting, and the original EX is not changed to E0.
Conditions for verification: Retain unverified prespecification and the unverified registration field, and disclose 0 current comparisons with registration/plans
Why this condition is needed: Needed to avoid mistaking the selected endpoint label for a prespecified 1st endpoint designation
Application exceptions: Unverified registration does not establish nonregistration or selective reporting
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N21 · How different are the supportive meta-analysis's unique trials, effects and conditions?

Current findings: The meta-analysis reports 12 unique RCTs and 13 SBP effect sizes; WMD −5.03 mmHg, 95% CI −8.49~−1.57, P=.004, with low certainty. The rationale specifies differences in baseline pressure, disease, formulation and dose, and some 2nd blood-pressure endpoints. Included trials, mapping of the 13 effects, inclusion of S01, and detailed heterogeneity/GRADE tables remain unread.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The reported pooled result, low certainty and different conditions are retained. The 13 effects are not counted as 13 unique studies, nor as 1+12 independent trials, and GRADE was not newly performed.
Reason for missing information: The reported pooled result, low certainty and different conditions are retained. The 13 effects are not counted as 13 unique studies, nor as 1+12 independent trials, and GRADE was not newly performed.
Required materials and conditions: The mapping of 12 unique RCTs and 13 SBP effects, populations/baseline pressure/formulations/doses/endpoint hierarchy, heterogeneity and detailed GRADE domains
Materials to obtain first: Meta-analysis included-trial/effect mapping tables, subgroup/heterogeneity analyses and GRADE domain tables
Further research: Material needed: Meta-analysis included-trial/effect mapping tables, subgroup/heterogeneity analyses and GRADE domain tables. This records needed materials; no new research was executed.
Remaining uncertainty: The reported pooled result, low certainty and different conditions are retained. The 13 effects are not counted as 13 unique studies, nor as 1+12 independent trials, and GRADE was not newly performed.
Conditions for verification: Retain the original 12 RCTs/13 effects, different conditions, some 2nd blood-pressure endpoints and low certainty; leave trial-specific distributions and inclusion of the direct trial unverified
Why this condition is needed: Needed to avoid presenting a positive pooled-average signal as independent replication of a single comparison
Application exceptions: Do not turn 13 effect sizes into 13 unique studies or add the direct trial as 1+12
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N22 · Does the material answer questions about optimal dose, long-term persistence or subgroups?

Current findings: The current direct comparison specifies 2 g/day for 12 weeks. The advertising interpretation rejects an optimal-dose conclusion for 2 g or more, and dose-response in the meta-analysis title does not provide a direct dose comparison. Long-term/post-withdrawal follow-up, prespecified subgroups and the diabetes analysis identity are also unverified.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Extension material beyond the narrow question was not read. Not every extension trial is made mandatory, and direct dose, persistence or subgroup effects are not promoted to verified status.
Reason for missing information: Extension material beyond the narrow question was not read. Not every extension trial is made mandatory, and direct dose, persistence or subgroup effects are not promoted to verified status.
Required materials and conditions: Direct dose comparisons, withdrawal/long-term follow-up, prespecified subgroups/interactions and the identity of the diabetes analysis
Materials to obtain first: Direct dose-comparison trials, post-withdrawal/long-term follow-up, subgroup plans and original results
Further research: Material needed: Direct dose-comparison trials, post-withdrawal/long-term follow-up, subgroup plans and original results. This records needed materials; no new research was executed.
Remaining uncertainty: Extension material beyond the narrow question was not read. Not every extension trial is made mandatory, and direct dose, persistence or subgroup effects are not promoted to verified status.
Conditions for verification: Treat the current 2 g/day and 12 weeks only as the trial specification, separating unverified direct evidence for optimal dose, persistence and subgroups
Why this condition is needed: Needed to avoid extending 2 g/day, 12 weeks and a meta-analysis title into optimal dose, persistence or diabetes effects
Application exceptions: Do not require every extension trial for the narrow 12-week SBP question
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N23 · Does an SBP change also answer questions about event prevention or medication replacement?

Current findings: The scope note limits the verdict to office SBP, and the advertising interpretation places antihypertensive replacement and cardiovascular-event prevention outside the evidence. The key explanation's roughly 5 mmHg signal is a low-certainty short-term pooled estimate, not a result limited to hypertension-treatment trials.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The boundary between the selected endpoint and clinical extensions is verified, but direct event/treatment-replacement results, denominators and follow-up are unverified within the current material. This gap does not remove the SBP report.
Reason for missing information: The boundary between the selected endpoint and clinical extensions is verified, but direct event/treatment-replacement results, denominators and follow-up are unverified within the current material. This gap does not remove the SBP report.
Required materials and conditions: Separate questions and direct evidence for the selected SBP outcome versus cardiovascular events, quality of life, mortality and antihypertensive replacement
Materials to obtain first: Separate plans, denominators, follow-up and results actually comparing events or treatment replacement
Further research: Material needed: Separate plans, denominators, follow-up and results actually comparing events or treatment replacement. This records needed materials; no new research was executed.
Remaining uncertainty: The boundary between the selected endpoint and clinical extensions is verified, but direct event/treatment-replacement results, denominators and follow-up are unverified within the current material. This gap does not remove the SBP report.
Conditions for verification: Keep the office-SBP boundary and do not present event prevention or replacement as currently verified results
Why this condition is needed: Needed to avoid converting a blood-pressure signal into cardiovascular-event prevention or treatment replacement
Application exceptions: Because SBP itself is the question, absence of event trials does not remove direct SBP reporting
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N24 · What level of harm verification is represented by the caution in the efficacy summary?

Current findings: The original safety label is Caution. The retained safety wording is: monitor dizziness, hypotension and possible interactions when combined with blood-pressure medicines, and do not reduce prescribed treatment on one's own. Actual observed adverse events, collection methods, event/safety denominators and discontinuation results are not linked in the current summaries of both efficacy reports.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The general caution is retained, but it does not verify actual harm records for the same exposure and population. An efficacy summary is not filled in as evidence of safety.
Reason for missing information: The general caution is retained, but it does not verify actual harm records for the same exposure and population. An efficacy summary is not filled in as evidence of safety.
Required materials and conditions: Actual adverse events, collection methods, denominators, discontinuations and the original caution for the same population, powder and period
Materials to obtain first: Adverse-event collection methods, event/exposure denominators, discontinuations and observation periods for the trial
Further research: Material needed: Adverse-event collection methods, event/exposure denominators, discontinuations and observation periods for the trial. This records needed materials; no new research was executed.
Remaining uncertainty: The general caution is retained, but it does not verify actual harm records for the same exposure and population. An efficacy summary is not filled in as evidence of safety.
Conditions for verification: Retain dizziness, hypotension and interaction cautions as the original narrative, separately showing unverified observed events, frequencies and discontinuations
Why this condition is needed: Needed to avoid converting the existence of an efficacy/meta-analysis summary into verified safety
Application exceptions: Unverified harm information does not remove the original SBP report or justify filling in safety
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N25 · Are dizziness and hypotension actual observed events or cautionary statements?

Current findings: Dizziness, hypotension and interactions are listed in the current safety caution and product information. Observed values for event diagnosis, occurrence/worsening, collection, severity and discontinuation could not be verified in the retained summary.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Recommendations are not converted into actual events or confirmed diagnoses, and absence of adverse-event reporting in the unread external article is not established.
Reason for missing information: Recommendations are not converted into actual events or confirmed diagnoses, and absence of adverse-event reporting in the unread external article is not established.
Required materials and conditions: Trial event definitions/adjudication, systematic or spontaneous collection, severity and discontinuation records
Materials to obtain first: Original adverse-event definitions, collection/adjudication procedures, and event, severity and discontinuation tables
Further research: Material needed: Original adverse-event definitions, collection/adjudication procedures, and event, severity and discontinuation tables. This records needed materials; no new research was executed.
Remaining uncertainty: Recommendations are not converted into actual events or confirmed diagnoses, and absence of adverse-event reporting in the unread external article is not established.
Conditions for verification: Separate the original caution wording from unverified current information on adverse events and their collection
Why this condition is needed: Needed to avoid converting recommendations into actual events or confirmed diagnoses
Application exceptions: Retain the original caution list without inventing observed events
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N26 · Is the temporal relationship between exposure and actual harm verified?

Current findings: Nominal administration of 2 g/day for 12 weeks is recorded. Actual harm onset, discontinuation, recovery, re-exposure and event-specific observation periods for this trial are not provided.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Treatment duration is not converted into event-onset or recovery timing. Original records needed to verify temporal order and harm causality remain unread.
Reason for missing information: Treatment duration is not converted into event-onset or recovery timing. Original records needed to verify temporal order and harm causality remain unread.
Required materials and conditions: Starting 2 g/day, the 12-week period, event onset/recovery, discontinuation/re-exposure and observation periods
Materials to obtain first: Exposure/event timelines and records of discontinuation, recovery and re-exposure
Further research: Material needed: Exposure/event timelines and records of discontinuation, recovery and re-exposure. This records needed materials; no new research was executed.
Remaining uncertainty: Treatment duration is not converted into event-onset or recovery timing. Original records needed to verify temporal order and harm causality remain unread.
Conditions for verification: Distinguish the 12-week treatment specification from unverified timing of actual events, discontinuation and re-exposure
Why this condition is needed: Needed to avoid inferring harm-onset or recovery timing from treatment duration alone
Application exceptions: Do not fill in temporal order or causality without discontinuation/re-exposure records
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N27 · Against which comparator were harms actually compared?

Current findings: Starch placebo plus the same lifestyle counseling specifies the efficacy comparison. Actual adverse events by group and comparative harm estimates are unavailable in the retained summary.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Verifying an efficacy comparator does not verify comparative harm results. Background incidence or increased risk is not extrapolated.
Reason for missing information: Verifying an efficacy comparator does not verify comparative harm results. Background incidence or increased risk is not extrapolated.
Required materials and conditions: Actual adverse events and comparative estimates involving placebo, background conditions and concomitant medications
Materials to obtain first: Adverse-event tables by group and event-specific comparison denominators/analyses
Further research: Material needed: Adverse-event tables by group and event-specific comparison denominators/analyses. This records needed materials; no new research was executed.
Remaining uncertainty: Verifying an efficacy comparator does not verify comparative harm results. Background incidence or increased risk is not extrapolated.
Conditions for verification: Record the starch-placebo/same-counseling comparison separately from unverified comparative harms by group
Why this condition is needed: Needed to avoid converting an efficacy comparison with starch placebo into observed comparative harm results
Application exceptions: When an efficacy comparator exists but harm-event tables do not, leave comparative harms unverified
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N28 · Are denominators and exposure time available for harm frequency?

Current findings: The 38 randomized participants, 37 completers (19/18), and the meta-analysis's 12 RCTs/13 effects are efficacy/reporting denominators. No linked adverse-event table supplies a safety-analysis denominator, people/event counts, exposed participants or exposure time.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The denominators, time and events needed to calculate current harm incidence are unverified. Do not create 0 events/0% or reuse efficacy denominators as safety denominators.
Reason for missing information: The denominators, time and events needed to calculate current harm incidence are unverified. Do not create 0 events/0% or reuse efficacy denominators as safety denominators.
Required materials and conditions: Numbers exposed or in the safety analysis, people with events versus event counts, and exposure/follow-up time
Materials to obtain first: Safety-analysis populations, people/event counts and exposure-duration tables
Further research: Material needed: Safety-analysis populations, people/event counts and exposure-duration tables. This records needed materials; no new research was executed.
Remaining uncertainty: The denominators, time and events needed to calculate current harm incidence are unverified. Do not create 0 events/0% or reuse efficacy denominators as safety denominators.
Conditions for verification: Do not reuse randomized/completer efficacy denominators as safety denominators; retain unverified event, exposure and follow-up denominators
Why this condition is needed: Needed to avoid converting 38 randomized participants, 37 completers or the meta-analysis's 12 trials into an adverse-event incidence denominator
Application exceptions: Do not calculate 0 events, 0% or a denominator from a current summary without events
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N29 · What alternative explanations involve concomitant medications, baseline conditions or lifestyle changes?

Current findings: The direct trial's population details exclude antihypertensive users, whereas the safety wording cautions about combining ginger with blood-pressure medicines. Records of other concomitant medications, underlying diseases, lifestyle changes, actual alternative explanations for harm or their adjustment are unavailable for this trial.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: A general combination-use caution is not attributed as an observed interaction in a direct trial excluding antihypertensive users. Absence of other causes is not inferred.
Reason for missing information: A general combination-use caution is not attributed as an observed interaction in a direct trial excluding antihypertensive users. Absence of other causes is not inferred.
Required materials and conditions: Exclusion of antihypertensive users, other medications/diseases, lifestyle counseling, dose and their relationship to actual harms
Materials to obtain first: Concomitant medications, underlying conditions, lifestyle changes and adjustment records in harm cases/trials
Further research: Material needed: Concomitant medications, underlying conditions, lifestyle changes and adjustment records in harm cases/trials. This records needed materials; no new research was executed.
Remaining uncertainty: A general combination-use caution is not attributed as an observed interaction in a direct trial excluding antihypertensive users. Absence of other causes is not inferred.
Conditions for verification: Distinguish medication-user exclusion in the direct trial from the general antihypertensive-combination caution, retaining unverified other concomitant exposures and alternatives
Why this condition is needed: Needed to avoid converting an interaction caution into direct verification of harm from combined use in this trial
Application exceptions: Do not describe an undocumented concomitant exposure as absent
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N30 · What is known about harm collection, reporting and loss to follow-up?

Current findings: Direct-trial completion counts and completer-analysis limitations are retained, but original records of adverse-event collection, selection/recall/detection, missing safety follow-up and discontinuation reasons were not read in this work.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Unverified information in a summary is not converted into confirmed nonreporting of harms in the original article, absence of harm or a known extent of missingness.
Reason for missing information: Unverified information in a summary is not converted into confirmed nonreporting of harms in the original article, absence of harm or a known extent of missingness.
Required materials and conditions: Collection of all adverse events, selection/recall/detection, missing safety follow-up and reasons for discontinuation/dropout
Materials to obtain first: Original collection procedures and the reporting scope for all adverse events, discontinuations and dropouts
Further research: Material needed: Original collection procedures and the reporting scope for all adverse events, discontinuations and dropouts. This records needed materials; no new research was executed.
Remaining uncertainty: Unverified information in a summary is not converted into confirmed nonreporting of harms in the original article, absence of harm or a known extent of missingness.
Conditions for verification: State that the current retained summary cannot establish collection, selection or missingness, without estimating the extent of actual missing harms
Why this condition is needed: Needed to avoid converting omissions in a summary or a completer analysis into absence of harms
Application exceptions: Because the external full text was not read, nonreporting of adverse events in the original article is not established
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01

N31 · Are the same harm events linked in other independent material?

Current findings: The current retained material contains a direct efficacy report, a meta-analysis and general safety cautions. Identities and repeat reporting/citation of separate independent harm events or materials are not linked, and no new safety search was performed.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Meta-analysis, Korean/English repetition and caution wording are not counted as independent events. Unconfirmed unique harm replication or total safety-study counts do not mean 0 studies.
Reason for missing information: Meta-analysis, Korean/English repetition and caution wording are not counted as independent events. Unconfirmed unique harm replication or total safety-study counts do not mean 0 studies.
Required materials and conditions: Identities of unique events/study families, reports and repeat citations, matched exposure/events and regulatory material
Materials to obtain first: Independent original safety reports with specified identities and exposures/events, and a repeat-citation mapping table
Further research: Material needed: Independent original safety reports with specified identities and exposures/events, and a repeat-citation mapping table. This records needed materials; no new research was executed.
Remaining uncertainty: Meta-analysis, Korean/English repetition and caution wording are not counted as independent events. Unconfirmed unique harm replication or total safety-study counts do not mean 0 studies.
Conditions for verification: Retain the limited fact that independent harm cases/families are unverified in both stored efficacy reports, without inventing replication counts
Why this condition is needed: Needed to avoid counting meta-analysis, caution wording and Korean/English repeat citations as independent repetitions of events
Application exceptions: Do not search for new safety material here or convert unverified status into 0 harm studies
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N32 · Does the material address long-term or rare harms and other vulnerable populations?

Current findings: The current direct comparison concerns adults with metabolic syndrome not using antihypertensives over 12 weeks. Direct safety material on long-term or rare events, combined medication use, pregnancy and other vulnerable populations is outside the current verified scope.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: A limited efficacy population/period is not extended into overall safety. The narrow SBP question does not require every long-term or rare-harm trial.
Reason for missing information: A limited efficacy population/period is not extended into overall safety. The narrow SBP question does not require every long-term or rare-harm trial.
Required materials and conditions: Exposure beyond 12 weeks and separate direct material on rare events, medication users, pregnancy/baseline risk and interactions
Materials to obtain first: Safety observation, comparison and registration material suited to the target vulnerable population and duration
Further research: Material needed: Safety observation, comparison and registration material suited to the target vulnerable population and duration. This records needed materials; no new research was executed.
Remaining uncertainty: A limited efficacy population/period is not extended into overall safety. The narrow SBP question does not require every long-term or rare-harm trial.
Conditions for verification: Separate the current population/12-week period from unverified long-term, combined-medication and special-population safety
Why this condition is needed: Needed to avoid extending short-term material in a limited population not using antihypertensives into safety for everyone
Application exceptions: Do not require every long-term or rare-harm trial for the narrow SBP question
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02

N33 · Does the current caution wording describe a signal, incidence or causality?

Current findings: The current caution and wording about monitoring combined use with blood-pressure medicines and avoiding self-directed dose reduction are retained. They do not verify event counts, comparative risk, causality or a safety grade in this trial; harm design, denominators, timing and alternatives remain unverified.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: This verifies the interpretation boundary and retained uncertainty of a cautionary statement. It does not create a new judgment that harm occurred or safety was established, or provide personal dosing instructions.
Reason for missing information: This verifies the interpretation boundary and retained uncertainty of a cautionary statement. It does not create a new judgment that harm occurred or safety was established, or provide personal dosing instructions.
Required materials and conditions: The reporting level of the original caution, actual design/events/denominators/timing/alternatives and possible interpretation
Materials to obtain first: Actual original harm material linking design, comparison, denominators, timing and alternative explanations
Further research: Material needed: Actual original harm material linking design, comparison, denominators, timing and alternative explanations. This records needed materials; no new research was executed.
Remaining uncertainty: This verifies the interpretation boundary and retained uncertainty of a cautionary statement. It does not create a new judgment that harm occurred or safety was established, or provide personal dosing instructions.
Conditions for verification: Retain the original caution as a limited statement, without presenting actual causal effects, frequencies or safety certification as verified in the current trial
Why this condition is needed: Needed to avoid promoting a general caution into harm causality, incidence or a new safety grade
Application exceptions: Do not create personal dosing instructions or a new efficacy/safety judgment
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources S01 S02